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 2 Abstract 
 
Breast cancer is the most common cancer in women worldwide and endometrial cancer 
is the fourth most common cancer in Western countries. Given the established role of 
estrogen in the development of breast and endometrial cancer, we surmised that common 
genetic variation in the pathways of hormonal exposure and response may alter 
individual responses to endogenous estrogen and consequently modify hormonal related 
cancer risk. Therefore, I used a candidate gene based approach in three independent 
studies to systematically investigate DNA polymorphisms within 37 genes of the 
estrogen metabolism pathway and 60 genes encoding ER-cofactors in samples of 
European ancestry to ascertain whether these genetic variants could modify the risk of 
breast and/or endometrial cancer. 
In the first study, polymorphisms within the androgen-to-estrogen conversion sub-
pathway were found to be associated with both breast (pglobal=0.008) and endometrial 
cancer (pglobal=0.014) in the Swedish population. This was validated in a Finnish sample 
of breast cancer (pglobal=0.015). Furthermore, it was showed that the sub-pathway 
association was largely confined to postmenopausal women with sporadic ER positive 
tumors (pglobal=0.0003), and CYP19A1 and UGT2B4 are the major players within the 
sub-pathway.  
In the second study, it was shown that six SNPs located within PPARGC1B, encoding an 
ER co-activator, showed consistent association with ER-positive breast cancer in 
Swedish and Finnish samples with the strongest association at rs741581 (OR = 1.41, P = 
4.84 × 10-5).  Interestingly, a significant synergistic interaction effect between the 
genetic polymorphisms within PPARGC1B and ESR1 was observed in ER-positive 
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breast cancer (Pinter = 0.008).  This genetic interaction is biologically plausible, because 
PPARGC1B was shown to augment the transcriptional regulation activity of ER, and the 
expression of PPARGC1B can be directly regulated by ER.  
In the last study, we found no significant association between individual SNPs or genes 
and the risk of endometrial cancer. Although the marginal association of the cumulative 
genetic variation of the NCOA2 complex as a whole (NCOA2, CARM1, CREBBP, 
PRMT1 and EP300) with endometrial cancer risk was observed (Padjusted=0.033), the 
association failed to be demonstrated in an independent European dataset. 
Overall, the findings from the current studies reflect the complex genetic architecture of 
breast and endometrial cancers where individual variants have very moderate impact on 
risk that are too weak to be detected by single variant analysis in moderate sample sizes.  
By targeting the cumulative effect of multiple variants, multi-variant analysis has better 
power for detecting the overall contribution of these variants to disease risk. The 
combination of multi-variant analysis with biochemically and genomically informed 
candidate genes, particularly through pathway-based studies, can enhance the discovery 
of moderate disease susceptibility alleles and their interactions. The findings in the 
current studies may help to improve our understanding on the genetic basis of breast 
cancer risk and facilitate the effort of identifying women with high risk for breast cancer. 
Further studies will be needed to examine if common variants with weaker effects or 
rare variants with larger effects within these genes may play a role in influencing breast 
or endometrial cancer risk.  
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 6 Introduction 
 
With more than one million women diagnosed with breast cancer each year worldwide, 
breast cancer is the most common cancer in women. Endometrial cancer is the seventh 
common cancer in women worldwide and the fourth common cancer in developed 
countries (1).  
It is generally accepted that cumulative, excessive exposure to endogenous estrogen 
across a woman’s lifespan contributes to the risk of developing breast cancer (2). It is 
also recognized that high circulating levels of unopposed estrogen (i.e. estrogen in the 
absence of progesterone) is a major risk factor for endometrial cancer (3). In vitro and in 
vivo animal studies as well as patient-based studies suggested that endogenous estrogens, 
their metabolic compounds and the estrogen-related metabolic machinery play important 
roles in breast and endometrial carcinogenesis (3,4). Observational studies also disclosed 
a influence of exogenous hormones such as hormone replacement therapy (HRT) (5,6) 
and oral contraceptives (OC) (7,8) in the two types of carcinogenesis. Molecular studies 
disclosed that cells respond to estrogen via estrogen receptors (ERs) through a defined 
biochemical process: upon ligand binding, ERs undergo a conformational change that 
facilitates receptor dimerization, DNA binding, recruitment of ER cofactors, and 
modulation of target gene expression(9).  Therefore, targeting estrogen signaling at the 
level of estrogen production and ER function are primary strategies for therapeutic 
intervention in hormone-dependent cancers. Also, components of enzymes and genes 
that regulate estrogen homeostasis might provide novel drug targets, tumor prevention 
and therapeutic opportunities. 
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Twin studies suggested that heredity may account for about 27% of breast cancer in 
Nordic countries (10). Another study conducted in England and Wales estimated that 
29% of breast cancer could be explained by heritable factors in young adult twins (11).  
As of today around 20~27% of familial breast cancer have been attributed to rare genetic 
variants of high penetrance in a number of genes, namely Breast cancer early onset 
1(BRCA1), Breast cancer early onset 2 (BRCA2), Phosphatase and tensin homolog 
(PTEN), Tumor protein 53 (TP53) (12-14) Ataxia telangiectasia mutated (ATM), CHK2 
checkpoint homolog (CHEK2), BRCA1-interacting protein 1 (BRIP1) and Partner and 
localizer of BRCA2 (PALB2) that confer an approximately 2-fold increased risk (15,16). 
Many genetic studies have suggested that breast cancer and endometrial cancer are 
common, heterogeneous and polygenetic diseases, and it is unrealistic to expect that the 
genetic variance of these diseases could be explained by a few genes (17-20).  
In the recent year, the rapid technological advance has been making genotyping easier 
and more affordable and the completion of Linkage disequilibrium (LD) map for the 
human genome (International HapMap Project) has been making the data of genetic 
variation freely available(21). Moreover, the bank of biological material in Swedish and 
Finnish provided us a great platform to explore the genetic landscape for studying 
common and rare variants. In the projects underlying this thesis, I have studied two 
groups of genes encoding components of the estrogen metabolism pathway and estrogen 
receptor cofactors with the aims to identify susceptible women who carry certain genetic 
variants that could confer high risk of developing hormonal driven cancers. Although 
GWAS for breast cancer have identified at least 20 novel genetic risk loci that harbor 
common alleles that contribute to genetic susceptibility for breast cacinogenesis or 
breast tumor subtype since 2007 (17,22-30), a candidate gene-based approach is still an 
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efficient and practical way of employing biological knowledge to discover common and 
rare susceptibility loci (31,32). 
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 7 Background 
 
7.1 Breast and endometrial cancer and their risk factors 
7.1.1 Breast cancer incidence 
Breast cancer is the most common cancer in women(1) and the incidence is increasing. 
Globally, new cases of breast cancer accounted for 23% (1.38 million) of the total new 
cancer cases in 2008 (33). Over the latest 10 year period, the average annual rate of 
change in the age−standardized incidence of breast cancer (worldwide) is +0.6% (34). 
The incidence of breast cancer in Nordic countries is increasing over the past four 
decades as well (Figure7-1). 
Like most epithelial cancers, the age-specific incidence of breast cancer rises steadily 
with age. However, the pattern is distinct in breast cancer around climacteric age 
(Figure7-2): it increases sharply until age 50 years, pauses at the so-called 
Clemmensens’s hook due to menopause (35), then bulged after 55 years till the peak 
which is around 60 to 65 years old, and goes down at a slower pace after 65 years. It is 
reported that the median age at diagnosis for breast cancer was 61 years of age during 
the 2003-2007 (36). Thus, the probability of developing breast cancer is higher in 
postmenopausal women.  
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Figure7-1 Incidence rate of breast cancer in Sweden, Finland and Nordic countries. 
(1953-2008) 
Source: (34) 
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Figure7-2.  Age-specific incidence rate of breast cancer in Sweden, Finland and Nordic 
countries (2008). 
Source: (34) 
7.1.2 Endometrial cancer incidence 
Endometrial cancer is the seventh most common cancer worldwide, but its incidence 
varies among regions. The incidence is ten times higher in North America and Europe 
than in less developed countries; in these regions, endometrial cancer is the most 
common cancer of the female genital tract and the fourth most common site of 
malignancy after the breast, lung, and colorectal tract(37). The incidence is rising as life 
expectancy increases. The age-adjusted incidence is increasing even when corrected for 
hysterectomy(38). The rise has been associated with an epidemic of obesity and physical 
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inactivity (19). Data from the SEER study indicated that endometrial cancer is largely a 
disease of postmenopausal women, with a median age at diagnosis of 63 years. The 
overall annual incidence in North Europeans is 14.3 per 100,000; age-specific incidence 
is highest among women aged 65–75 years, exceeding 100 per 100,000 per year.  
Figure7-2 and 7-4 show that the rate of increase with age decreases around climacteric 
age in breast and endometrial cancer, which indicates that both incidence rates are 
related with ovarian function, and oophorectomy reduces the incidence significantly. 
Through a reduction in mitosis accompanied by a decrease in estrogen level, menopause 
slows the rates of induced mutations in the stem cells of specific organs, therefore, early 
menopause may have a protective effect on both cancers (39). However, there are subtle 
differences in the pattern of the age-specific incidence, like the clemmesen’s hook can 
be observed clearly in breast cancer but not apparently in endometrial cancer. Besides 
that, estrogen plus progestin therapy is a risk to breast cancer but not endometrial cancer; 
oral contraceptive use is a protective factor for endometrial cancer but not breast cancer 
etc. Such phenomena may be explained by the different effects of estrogen on cell 
division rates (39) and genetic susceptibility on the two organ sites (40). Given estrogen 
related pathways on endometrial carcinogenesis is an important theme, genetic variation 
in estrogen regulation pathway and cellular response to estrogen pathway may contribute 
to the carcinogenesis. The genetic association study performed on these two diseases 
may help to disclose the similarity and differences further.
  19 
 
Figure7-3 Incidence rate of endometrial cancer in Sweden and Nordic countries.(1953-
2008) 
Source: (34) 
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Figure7-4.  Age-specific incidence rate of endometrial cancer in Sweden and Nordic 









7.1.3 Risk factors for breast and endometrial cancer 
Risk factors for breast cancer have been categorized as modifiable factors and 
unavoidable factors by Howell A et al  (41). As Figure7-5 shows, modifiable factors are 
environmental factors, lifestyle factors and reproductive factors. Clear evidence for 
environmental factors come from studies of migrants, in which people that move from 
low to high incidence counties developed the higher incidence in their new countries (7). 
Other well-established modifiable risk factors appear to be certain reproductive factors 
( late 1st time full term pregnancy, less parity), body mass index, alcohol, physical 
activity, exogenous hormones ( OC use and HRT).  Unavoidable factors are genetic 
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factors comprised of high penetrance genes and low penetrance genes.  Mutations in 
high penetrance genes, like BRCA1,BRCA2 and TP53 etc account for 15%–25% of the 
familial component of breast cancer risk (14,42).  Much of the genetic component of risk 
of breast cancer is thought to arise from the combined effect of multiple low penetrant 
variants and remains uncharacterized (43). Estrogen is the centralized interactor of all 
modifiable and unavoidable risk factors.  
 
Figure7-5.Complex risk factors of breast cancer. From Howell A et al. (2005)   
Source: (41)
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Around 5-10% of endometrial carcinomas have a hereditary basis, in which non-
polyposis colorectal cancer (HNPCC) is the most common hereditary cause. Women 
with HNPCC have a lifetime risk of 42% for endometrial carcinoma. In families affected 
by HNPCC, the median age of occurrence is 46-year old, which is 15 to 20 years 
younger than the median age at diagnosis in the general population(44). However, the 
majority of cases are sporadic and mainly driven by hormonal exposure (37), such as 
unopposed estrogen treatment, polycystic ovarian disease and estrogen-producing 
tumors. High levels of endogenous estrogen is associated with being overweight or 
obese, early menarche, late menopause and nulliparity (45). Cohort studies in 
postmenopausal women (46-49) have shown strong associations between endometrial 
cancer and serum levels of estradiol and estrone, even after controlling for body mass 
index and other factors. Exogenous estrogen levels increase with menopausal estrogen 
therapy (without use of progestin) and tamoxifen use(50). Pregnancy and the use of 
combined oral contraceptives (COCs) (51) provide  protection against endometrial 
cancer.  
In addition, women with a positive history of breast cancer have higher risk of 
developing endometrial cancer. The risk of developing a serous endometrial cancer was 
2.6 times higher than the risk of developing an endometrioid carcinoma (3,52). 
Moreover, tamoxifen use, which is shown to be an effective endocrine treatment and 
prevention approach for postmenopausal breast cancer patient (50), also increases the 
chance of developing benign endometrial lesions (34-36). Although the mechanism 
behind this action is unclear, it is suggested that the overall tissue-specific coregulators 
and balance of the relative expression levels of coactivators and corepressors may be 
important determinants underlying the differential effects on risk (53). 
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7.2 Subtypes of breast and endometrial cancer 
Classification of breast cancer into intrinsic subtypes or clinical subgroups could be 
important for the proper prediction, selection of therapy and estimation of prognosis. 
Based on ERα protein expression, breast cancer has been subgrouped as ER positive 
tumor and ER negative tumor. ERα is detected more frequently in postmenopausal 
breasts, and is reported to increase positively with age(54). ER positive breast cancer is 
well-recognized as a hormonal driven tumor, which accounts for 70-85% of overall 
breast cancer. Since the last decade, microarray techniques have been widely used to 
explore cancer biology. Based on gene-expression profiling(55,56) breast cancer has 
been classified into four groups: a) basal-like breast cancer, which is  also called as 
“triple-negative” tumors and is defined as lack expression of ER, PR and HER-2; b) 
Luminal-A cancer, which is mostly ER-positive and histologically low-grade; c) 
Luminal-B cancer, which is mostly ER-positive but express low levels of hormone 
receptors and are often high-grade; and d) HER-2 positive cancers, which show 
amplification and high expression of the HER-2 gene and several other genes of the 
HER-2 amplicon (55,56) . Basal-like cancer have less favorable outcomes (57), while 
Luminal-like (mostly are ER positive) tumors have a more favorable outcome and HER2 
subgroups are more sensitive to chemotherapy. Although, well-designed 
epidemiological studies are necessary as a first step toward biological annotation, high-
fidelity models of breast cancer to efficiently and accurately test the roles of genes or 
pathways in particular subtypes of cancer biology is also needed. The advent of 
sequencing approaches may disclose the cancer genome in single nucleotide level. A 
recent publication reported that next generation sequencing approaches with single 
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nucleotide resolution may help to examine the progression of ER positive breast tumors 
(58).  
According to the system of the International Federation of Gynecology and Obstetrics 
(FIGO)(59) and modified criteria (60), endometrioid carcinoma has been categorized 
into three grades. Basically, grade1 carcinoma is an ER positive tumor which consists of 
well-formed glands and less than 5% of solid non-squamous areas, grade 2 contains 
6~50% of solid non-squamous areas and grade 3 is defined as having more than 50% 
solid growth, diffusely infiltrative growth and/ or tumour-cell necrosis. Grade 2 and 
grade 3 tumors frequently do not express ER protein receptors. Based on histological 
grading and prognosis, two different clinic-pathological subtypes of endometrial cancer 
are recognized (37). Type I endometrial cancer accounts for approximately 70~94% of 
endometrial carcinomas and is associated with long-duration unopposed estrogenic 
stimulation (3,61). This type of cancer is well to moderately differentiated and arised on 
a background of endometrial hyperplasia. Therefore, the tumor is low-stage, low-grade, 
hormonal-driven and women with such tumor have a favourable prognosis. PTEN 
polymorphisms are reported in 25~83% overall endometrial cancer (62) and more 
frequently in type I tumors. In contrast, about 10% of endometrial cancers are type II 
lesions (61). These tumors are not estrogen-driven, are associated with a poor prognosis, 
as characterized by a high-stage and high-grade, and either poorly differentatied 
endometrioid or non-endometrioid histology. TP53 mutations are considered to be an 
early event in type II tumors (80-90%) and a late event for type I tumors (5-10%)(62).  
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7.3 Determination of ER phenotype and reliability of 
testing 
ER status is one of most important clinical predictors of breast cancer treatment, in 
which the endocrine therapy is beneficial for ER-positive patients, whereas, the 
chemotherapy is favoured for ER-negative patients (63,64). Therefore, it is important to 
evaluate and determine the extent of the presence of the estrogen receptor biomarker in a 
breast cancer study.  
 
The methods and standards for ER testing tend to vary across study populations and over 
time. The primary method used for ER detection was the dextran-coated charcoal assay 
(DCC) based on ligand-binding first described by McGuire in 1973(65), with results 
being expressed as fmol/mg cytosol protein. The main advantage of this method is the 
direct quatification of receptor levels which aids the prediction of ER status. However, 
this assay required fresh tissue and the level of receptor detected could be influenced by 
the presence of large amounts of normal breast or stroma tissue. Therefore, the 
Immunohistochemistry (IHC) method has been increasing used for ER detection and is 
expected to be clinically comparable to the DCC method. A comparative study was 
conducted by The International Breast Cancer Study Group, in which the samples 
originally tested by the DCC method were re-assessed by IHC with standardized fixation 
in a central laboratory (66). A good concordance rate was observed between the two 
assays, which indicated that IHC method (positive >= 10%) has a similar predicative 
value as the original DCC method (positive >15 fmol/mg protein) if optimal fixation and 
a high standard of quality assurance are used. Another study comparing the two methods 
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was performed by Harvey JM et al (67) , based on 1982 primary breast cancer patients 
and found that IHC is an easier, safer,  cheaper method for assessing ER status with 
equivalent or better accuracy.  
 
Currently, IHC method is a commonly used assay for the determination of ER status. 
This method is based on a specific antibody binding to its antigen and has the following 
elements: 1) the sample is formalin-fixed and paraffin-embedded, 2) the antigen retrieval 
process, 3) specific ER antibody-antigen binding, 4)generation of a color signal, 5) 
quantification of signal and 6) interpretation of signal. It can provide either dichotomous 
or more quantitative results. The major problem of IHC test is a high false-negative rate, 
which is estimated to be around 30% to 60% (68-71). To improve the test reliability, the 
following sources of variation in marker testing will need to be considered during each 
step. (Table 7-1) (72): 
Pre-analytic: 
Breast tissue can be obtained from either a needle core biopsy or breast resection 
specimen. Needle core breast biopsy is a standard method for non-operative diagnosis 
and has higher ER positive rate compared with excised tumors. Delayed fixation of the 
specimen after extraction may result in increased proteolytic degradation and lead to loss 
of immunoreactivity for the ER, therefore decrease the ER positive detection rate (73). 
The National Health Service Breast Screening Program (NHSBSP) recommends that 
surgically excised breast specimens should be sliced and fixed as soon as possible after 
surgery(73). It was recommended that 6-8 hours of tissue exposure to formalin will help 
in obtaining consistent ER results(74). Moreover, the over-fixation of samples will lead 
to decrease the ER detection rate. Variation in fixation time and methods between 
laboratories could influence the consistency of IHC results. For the embedded sections, a 
  27 
higher ER detection rate was usually obtained at the outer edges of the resection 
specimens, likely because of the incomplete fixation of the inner resection samples 
(75,76). Although the protein embedded in wax blocks is stable, there is evidence of 
deterioration of protein reactivity once paraffin sections have been cut (77). 
 
Table 7-1 Sources of ER status testing variation (Adapted from Wolff AC etc.(72)) 
Pre-analytic factors: 1. The way of tissue preparation. 
  2. Time to formalin-fixation. 
  3. Time and type of fixation. 
Analytic factors:   
  1. Assay validation 
  2. Equipment calibration 
  3. Use of standardized laboratory procedures 
  4. Training and competency assessment of staff 
  5. Type of primary antibody and second antibody 
  6. Type of antigen retrieval and test reagents 
  
7. Use of standardized negative control and 
positive control materials 
  8. Use of automated laboratory methods 
Post-analytic 
factors:   
  1. Interpretation criteria 
  2. Use of image analysis 
  3. Reporting elements 
  
4. Quality assurance procedures (laboratory 




Besides the standardized laboratory procedures and the calibration of the assay 
equipment, the level of training and competency of the laboratory technicians is an 
important factor influencing the consistency of IHC measurements. Antibodies against 
ER have been well-characterized and selected by comparisons with a “gold standard” 
and by the use of external quality assurance data from the UK National External Quality 
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Scheme (NEQAS). Two monoclonal antibodies, 1D5 and 6F11, have been validated to 
have specificity and sensitivity in ER detection (73). Inadequate antigen retrieval may 
contribute to variations in the extent of staining of test sections and the methods used for 
antigen retrieval may differ between laboratories. Antigen retrieval by enzymatic 
treatment often performs better than buffer heating and different buffers used for antigen 
retrieval can also influence results. Both negative and positive controls with same 
fixation, processing and testing conditions should be used for each test sample. In 
addition, different sensitivities of the assay system may affect the proportion and 
intensity of the stained cell detection. The use of a standardized assay system and 
automated image analysis may help to accurately and precisely assess staining intensity. 
To perform technically valid IHC assay, both external validation and internal validation 
are key components toward IHC standardization. External validation is done by 
examining the concordance between results obtained on the same set of samples in two 
different laboratories, at least one of which is well-estabalished to have a technically 
valid assay; internal validation is done by using a set of standard samples with 
established ER status previously determined though IHC testing by an organization such 
as National Institute of Standards and Technology (NIST) or College of American 
Pathologists (CAP). 
Post-analytic factors: 
Interpretation of IHC testing results involves the quantitative system (based on 
proportion of cells stained), the scoring systems (based on proportion of cells stained 
and the intensity of the staining), and the dichotomous system (established based on a 
cutoff value to distinguish a positive from a negative result). The dichotomous system is 
widely used in clinical practice (78) and is calibrated according to clinical outcome. 
External quality assurance, such as the guidelines from CAP may help to monitor the 
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quality of the laboratory method and results and to accurately determine the ER status of 
breast cancer tumors. 
 
7.4 Genetic polymorphisms in Estrogen Receptor 
In view of the estrogen receptor (ER) being important transcription factor belonging to 
the steroid hormone receptor super family, genetic variants of its two isoforms, ERα and 
ERβ have been evaluated for a role in influencing breast cancer risk. ERα is encoded by 
the ESR1 gene which is located on chromosome 6, and ERβ is encoded by the ESR2 
gene which is on chromosome 14 (79).  
Genetic variants of ESR1 have been well-studied in terms of association with breast 
cancer risk. Our previous study (80) suggested polymorphisms in a region between the 
SNPs rs3003925 and rs2144025 are associated with breast cancer risk in the Swedish 
population. Recently, three large GWAS have demonstrated the association between 
ESR1 and breast cancer risk as well. Stacey et al. (81) found an association of rs9397435 
with breast cancer risk in the European, Chinese and African population; Turnbull et al. 
(26) reported SNP that rs3735318 showed a significant association in a population of 
European ancestry; while Zheng et al (27) described a SNP rs2046210 associated with 
breast cancer risk among Chinese women. Although the three SNPs are in weak linkage 
disequilibrium with one another, all of them occur within the same locus, 6q25.1 around 
ESR1 and were associated with P values less 10E-6 in GWAS, the ORs varied from 1.14 
to 1.3 among different populations. Cai et al (82) further performed further genomic 
experiments and identified that a potential functional SNP rs6913578 which is highly 
correlated with the SNP rs2046210 and significantly altered DNA binding protein 
interactions. 
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In comparison to ESR1, the association between polymorphisms in ESR2 and breast 
cancer risk has been inconclusive. A few studies (83-85) with moderate sample size 
reported statistically significant associations, but none of them has been validated. Ke-
Da Yu et.al (86) conducted a meta-analysis to evaluate the relationship between two 
SNPs, rs4986938 and rs1256049 within the ESR2 locus and breast cancer risk. Although 
they found that rs4986938 was associated with a decreased risk in a dominant model of 
inheritance in the overall analysis of 10837 cases and 16021 controls, the ethnicity 
subgroup analysis did not reflect any positive finding. Therefore, a large well-designed 
study is warranted to further explore the association between genetic variants in ESR2 
and breast cancer risk. 
 
7.5 Candidate gene based genetic association study 
Candidate genes are chosen in genetic association studies based on previous knowledge 
of mechanisms of diseases. In breast and endometrial cancer, sexual homrone related 
genes are obvious targets. In this review, I will focus on two major groups of genes: 
genes involved in hormonal exposure (E2 metabolism) and genes involved in cellular 
exposure to hormone stimulation (ER cofactor).  
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7.5.1 Hormonal exposure: Genetic polymorphisms in 
Estrogen metabolisms pathway 
The results of clinical, epidemiological and biological studies have all demonstrated that 
excessive or prolonged exposure to unopposed estrogen increases the risk of breast and 
endometrial carcinomas. However, it is true that the majority of estrogen-dependent 
carcinomas occur during the postmenopausal period, when the ovaries cease to be 
functional or produce active sex steroids. Therefore, in situ estrogen metabolism and 
synthesis play substantial roles in the development and progression of various human 
estrogen driven tumors, including breast and endometrial carcinomas in postmenopausal 
women. Thus, it is very important to investigate the enzymes responsible for estrogen 
metabolism and biosynthesis.  
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Figure7-6 Subdivision of the estrogen metabolic pathway.
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7.5.1.1 Estrogen metabolism 
Estrogen is a steroid hormone that is synthesized from cholesterol via a series of 
reactions that takes place primarily in the ovaries in premenopausal women. After 
menopause, peripheral sites including the liver, breast, and adipose tissue become the 
major sites of estrogen production (87). In contrast to cyclic production in 
premenopausal women, estrogen production is constant in postmenopausal women(88).  
In general, the estrogen metabolism pathway involves three major stages (Figure 7-6). 
Stage I involves the synthesis of androgen by enzymes of the cytochrome P450 family 
(CYP11A1, CYP21A2 and CYP17A1) (89); Stage II involves the conversion of androgen 
to estrogen by the enzymes: steroid sulfatase isozyme S (STS), hydroxy-delta-5-steroid 
dehydrogenase 3 beta- and steroid delta-isomerase1 (HSD3B1), cytochrome P450 family 
19 subfamily A polypeptide 1 (CYP19A1) and others,  responsible for conversion of 
dehydroepiandrosterone sulfate (DHEAS) into 17 β-estradiol (89,90); Stage III involves 
two important steps: the removal of estrogen through the conversion of 17 β-estradiol 
into catechol metabolites and hydroxy derivatives by cytochrome P450 family enzymes 
(CYP1A1,CYP1A2 and CYP1B1) by hydroxylation and the inactivation and elimination 
of catechol estrogens by the processes of detoxification, oxidation, mythylation, 
sulfonation and glucuronidation by the enzymes catechol-O-methyltransferase (COMT), 
glutathione S-transferase family members (GSTs), sulfotransferase family members 
(SULTs) and UDP glucuronosyltransferase family members (UGTs) (88,89). 
The cytochrome P450 superfamily plays important role in the estrogen metabolism 
pathway, which catalyses a rate-limiting step in estrogen synthesis leading to the 
precursor, DHEAS, formation of oestradiol from testosterone and oestrone from 
androstenedione. CYP17A1 converts pregnenolone and progesterone to DHEAS, a 
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precursor for estrogen and testosterone production. Another family member, CYP19 is 
also called aromatase. Its activity determines the local estrogen level, as it might act to 
increase  levels of metabolites for enzymes, such as CYP1A1 and CYP1B1, and might 
lead to reduce protective conjugation, such as glutathione S-transferase M1 and catechol 
O-methyltransferase (91,92). Among the CYP superfamily, CYP1A1 catalyses the 2-
hydroxylation of estrogens, while CYP1B1 catalyses the 4-hydroxylation of estrogens 
which could activate the estrogen receptor, thereby increasing the quantity of estrogen 
within the cells. It is reported that the higher ratio between 4-hydroxylation and 2-
hydroxylation may initiate carcinomas in the endometrium (93). Many other cytochrome 
P-450 enzymes (including those coded for by CYP1A2, CYP1B1,CYP2A, CYP2B, 
CYP2C, CYP2E1, CYP3A, and CYP4B1) are involved in the activation or detoxification 
of drugs and other xenobiotic compounds (94). 
The enzymes COMT, GSTs, SULTs and UGTs are involved in the inactivation and 
elimination of catechol estrogens, which are in turn responsible for detoxification, 
oxidation, methylation, sulfonation and glucuronidation (88).Following the metabolic 
activation of estrogens (2- and 4-hydroxyestrogens), the catechol estrogens are 
inactivated by COMT (2- and 4-methoxyestrogens) or they are oxidized into quinones 
and semi-quinones (95),which are known to be estrogenic and are believed to be 
carcinogenic (96). Of these compounds, 2-methoxyestrogens do not induce DNA 
damaging events, but 4-methoxyestrogens form depurinating DNA adducts which can 
occur in vital genes that control metabolism of estrogens (88,97,98). Therefore, COMT 
is a key enzyme for preventing quinone and semiquinone formation via the methylation 
of hydroxyestrogens (99). GSTs, SULTs and UGTs inactivate any quinones or 
semiquinones formed, ultimately leading to their elimination (100,101). 
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Estrogen metabolic genes have been shown to have various functional effects on their 
encoded enzymes. Genetically altered activity of enzymes from the three stages may 
influence local hormone levels and cause variation in the extent of DNA damage. 
7.5.1.2 Genetic association study of estrogen metabolism genes 
Among cytochrome P450 super family, CYP17A has been widely studied. It was found 
women carrying heterozygous or homozygous -34 T/C (rs743572)(102) in 5` 
untranslated region may create an  Sp-1-type promoter site and therefore increase 
transcription, leading to high serum estradiol and progestin concentrations (103,104). 
However, the studies could not confirm whether the polymorphisms in this gene were 
associated with the risk of breast cancer or endometrial cancer (105-107) .  
Another family member, CYP19 is also named aromatase and its inhibitor (AI) is used 
for breast cancer endocrine treatment. Thus, polymorphisms in this gene may result in 
either increased or decreased aromatase activity, which indirectly affects estrogen levels, 
and may ultimately determine the development, treatment, and prognosis of breast 
cancer (108). A recent meta-analysis paper generalized (109) that (TTTA)10, a short 
tandem repeat in CYP19A1 may alter the mRNA splicing site, therefore increase risk of 
breast cancer.  
Other cytochrome P450 superfamily members have also been studied. Four 
polymorphisms (T3801C (rs4646903), T3205C, A2455G (rs1048943) and C2453A 
(rs1799814)) (110,111) in CYP1A1 gene have been widely studied in relation to breast 
cancer risk (112,113) . The first two polymorphisms are located within the 30-noncoding 
region, while the latter two result in Ile462Val (rs1799814) (111)and Thr461Asp 
variants (rs1799814) (111) in exon 7 respectively (112). Among them, the G allele of 
A2455G (rs1048943) has been reported to be significant associated with breast cancer 
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risk in two studies (113,114). However, the result is conflicting between the two studies: 
one reported the G/G genotype associated with  reduced breast cancer risk in east-Asian 
population and pre-menopausal women (114), while the other one pointed its increases 
breast cancer risk in Caucusian population (113). A coding variant Val432Leu 
(rs1056836) (115) allele on CYP1B1 has also been studied (116-118), however the 
results of increasing risk in breast cancer or endometrial cancer are not consistent.  
In view of the facts that single SNP analysis is good at identifying a number of the most 
significant SNPs but a small proportion of the genetic variants, a few studies attempt to 
address the question with gene-based or pathway-based approaches (19,98,108,118-121) 
in keeping with the polygene hypothesis of complex diseases. 
Ashton and colleagues (122) studied the association between 28 polymorphisms and 
endometrial cancer risk in Caucasian population. Those coding variants were located in 
18 genes including metabolism genes, coregulator gene (AIB1) and hormonal receptor 
genes (ESR1 & AR). Despite the small sample size (191 cases vs 291 controls), a 
plausible positive association between polymorphisms in the AR, CYP1A1, CYP1B1, 
ESR1 and GSTM1 and endometrial cancer risk have been reported. Another study which 
was conducted by Yang et.al(20) investigated 36 hormone-related genes in a Polish 
population. With a multi-locus analysis approach, they found CYP19A1 and AR showed 
borderline significant association with endometrial cancer risk.  
Justenhoven et al (19) studied 688 breast cancer cases and 724 controls from Germany 
to investigate 11 genes in the estrogen metabolism pathway. Although the interactions 
between single polymorphisms and BMI or HRT were identified, polymorphisms in 
metabolism pathway as a whole was not associated with breast cancer risk in a global 
test. Paul D.P and colleagues (118) conducted a large case-control study and 
investigated 120 candidate genes with 710 tag SNPs. They demonstrated that genes in 
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the pathways of cell-cycle control and estrogen metabolism showed significant 
association with breast cancer risk with the admixture maximum likelihood experiment-
wise test (AML). However, with the rank truncated product (RTP) method, the results 
were not significant.  
Genetic variation within the estrogen metabolic pathway has been intensively 
investigated, mostly by analyzing single variant effects in a limited number of candidate 
genes and SNPs. The results of a few pathway-based studies did not provide convincing 
results due to the absence of validation studies or alternative approaches for verification. 
Inadequacies of study design, such as limited sample size and inappropriate analytical 
methodologies may have caused these studies to be underpowered for detecting variants 
of moderate genetic effects. Besides, different LD pattern among populations, 
population stratification and sub-population heterogeneity could also have led to 
inconsistent results. 
7.5.2 Response to hormonal exposure: Genetic 
polymorphisms in ER cofactors 
The function of the estrogen receptor (ER) is regulated by ligand concentration, related 
transcriptional cofactors, post-translational modifications of the receptor and 
components of the ER complex. Given that molecular biology studies demonstrate 
physical and functional interactions between ER and ER cofactors, ER cofactors may 
play an important role in altering the cellular response to estrogen (123). ER cofactors 
include those that enhance the transcriptional activity of the receptor complex and those 
that negatively regulate ER functions (21,22). Since the first Nuclear coactivator1 
(NCOA1) was identified in 1995 (124), more than 200 nuclear coactivators and 40 
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nuclear corepressors have been identified to date (http://www.nursa.org )(125). ER 
cofactors appear to function by remodeling chromatin structures and/or acting as adapter 
molecules between transcription factors and the components of the basal transcriptional 
apparatus. Aberrant co-regulator expression and function may lead to altered regulation 
of ER activity and hormone signaling that may ultimately lead to tumor formation.  
7.5.2.1 Molecular function of ER coactivator and ER corepressor 
The estrogen receptors (ERα ) has three major functional domains (126): activation 
function-1 domain (AF-1), hormone-dependent activation function-2 domain (AF-
2)(53,54) and DNA-binding domain (DBD) (Figure7-7). Although AF-1 and AF-2 
contribute synergistically to the transcription of targeted genes, they have different 
mechanisms of activation in different cells, different promoter contexts and may bind 
with different ER cofactors (127). Therefore, ER cofactors may be grouped by the 
specific binding sites of ERα (Table7-1). 
Among the three groups, AF-2 coactivators have been well-studied. P160 steroid 
receptor family is one of the most widely-studied classical coactivators in AF-2 group, 
including nuclear coactivators 1 (NCOA1), nuclear coactivators 2 (NCOA2) and nuclear 
coactivators 3 (NCOA3). These cofactors contain intrinsic histone acetylase activity 
(HAT), which is known to facilitate chromatin remodeling at target promoters (63,64). 
As p160s contain not only LXXLL motifs to mediate their interaction with ER (128) but 
also contain C terminal activation domains (AD1 and AD2) and N-terminal basic helix-
loop-helix/PAS (bHLH/PAS) domains, which enables second coactivators involved in 
chromatin remodeling, to further enhance ERα transcriptional activity (129) (Figure 7-7). 
Specifically, AD1 recruits the histone acetyltransferases CBP and p300, and AD2 
interacts with proteins, such as coactivator associated arginine methyltransferase 1 
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(CARM1) and Protein arginine N-methyltransferase 1 (PRMT1). In addition, binding of 
the bHLH/PAS domain, coiled-coil coactivator (CoCoA), also enhances ER target gene 
expression by associating with p160s (130). The existence of these secondary 
coactivators allows for amplification of ER responses indirectly through interacting with 
the p160 coactivators, instead of binding the ERs in a direct manner. At the same time, 
the P160s interact with their secondary cofactors that enable them to manifest their 
effects on ER. Therefore, the P160 family members have various functions: a) integrate 
the transactivation complex into the basal transactivation machinery, and thereby 
specifically enhance the transactivation mediated by steroid receptors; b) recruit other 
co-activators to the transactivation machinery; c) possess histone acetyltransferase 
activity, and thus is able to remodel the chromatin structure and thereby enhance 
transcriptional activity. Besides P160 coactivators complex, there are several other 
coregulator-complexesthat are engaged in ER mediated transcriptional regulation, such 
as histone acetylation & methylation, RNA processing, histone deacetylases, ligand-
dependent corepressors and ATP-dependent chromatin remodeling complexes(131).  
Although the p160 family members exhibit significant structural homologies and may be 
partially functionally redundant, they exert different physiological functions. In vivo 
genetic studies on NCOA1-null mice has shown that, while both male and female 
NCOA1 knockout (KO) mice are fertile, they suffer from a partial resistance to several 
hormones that affects the endometrium and breast, including estrogen, progestin, 
androgen, and thyroid hormones (68). NCOA2 plays a critical role in the reproductive 
functions of the mouse asthe fertility of both male and female NCOA2 KO mice is 
impaired (69). Elimination of NCOA3 has revealed that it is required for normal mouse 
growth, as well as for some of the female reproductive functions (132).  
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Figure 7-7  The schematic structure of nuclear receptor and P160 family complex 
Source (133) 
 
Some coactivators have two functions to enhance transcriptional activity; these dual-
functional coactivators are shown in Table7-1 as well. The peroxisome proliferator-
activated receptor γcoactivator-1 (PGC-1) family includes PPARGC1A and PPARGC1B. 
Initially, they had been identified as transcriptional coactivators of the peroxisome 
proliferator-activated receptors (PPARs)(39); later, they were found to interact with ERs 
physically and functionally. E6-associated protein (E6-AP) and receptor potentiating 
factor-1 (RPF-1) are ubiquitin protein ligases that potentiate the ligand-dependent 
transcriptional activity of ER. They also have ability to ubiquitinate proteins prior to 
degradation by the 26S proteasome(133), which act to further enhance transcription of 
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ER target genes by catalyzing the dynamic exchange of ER, cofactors, and other 
transcriptional components(9). 




Another group of ER cofactors termed as corepressors have been identified to dampen 
the estrogen-ER actions via blocking access of AF-2 coactivators, interfering with 
NOCA1 access to the receptor(134), or associating with histone deacetylase (HDAC) 
complexes, which repress transcription by catalyzing the condensation of chromatin(9). 
Such corepressors include the nuclear receptor corepressor (NCoR), repressor of 
estrogen receptor activity (REA), silencing mediator for retinoid and thyroid receptors 
(SMRT) and receptor interacting protein of 140 KDa (RIP140) etc. Although the number 
of known ER corepressors is fewer than that of ER coactivators, corepressors play 
important roles in moderating the agonist activities of estrogens and provide an 
additional mechanism for fine-tuning the expression of ER target genes and attentuating 
the hormone level.  
In summary, the comprehensive network of coactivators and corepressors allows for 
balanced, sensitive control of ER target gene expression. 
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7.5.2.2 The constraints of ER cofactor study 
The complex network of ER cofactors provides a balanced and sensitive environment 
for ER transcriptional regulation and ER target gene expression. In general, ER 
cofactors have the ability to enable the ERs to respond appropriately to hormones or 
SERM ligands, catalyze the process of chromatin condensation and communicate with 
the general transcription factors at target gene promoters. However, precise 
classification and clear elucidation of the functions of each ER cofactor are unrealistic 
with current knowledge. There are several reasons:  a) some cofactors do not have any 
known direct effects on chromatin structure or modification, but instead may perform 
assembly functions, such as recruitment or release of cofactor complexes (131); b) new 
coregulators have been identified; c) most of the coregulators have the ability to regulate 
the activities of several other NR family members, which make it difficult to identify 
specific roles of different coregulators in ER physiology and pathology  (there is a need 
to develop new technology for the assessment of specific ER-coregulator pairs in vitro 
and in vivo)(131); d) due to ER subtype, tissue-specific, promoter context and cell 
signaling events, ER action itself is complex, thus, it is difficult to using simple 
experiments to dissect distinct functions of ER cofactors (123); e) the complex of large, 
high molecular weight coregulators has a fundamental role in determining its flexibility, 
and provides a conceptual basis for the exquisite control of specific gene expression; on 
the other hand, it also increases the complexity of cofactor function, as each component 
is capable of several interactions (131,133); f) the existence of cofactor protein 
complexes allows for a temporal- and tissue-specific modulation of the combinatorial 
cofactor and histone codes for single genes, which further increases the complexity of 
their transcriptional regulatory roles (53,133). 
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7.5.2.3 Genetic association study of  ER cofactor genes 
NCOA3 and CCND1 have been extensively studied in the influence of coding variants in 
these genes on breast cancer risk (135-144) (See Appendix 1). A protective effect has 
been reported with the coding variant Gln586His (rs2230782) (145) variant in NCOA3 
in a European study (775 cases and 1,628 controls) (137), however another study which 
was conducted in 1,612 invasive breast cancer cases and 1,961 controls in multi-ethnical 
panel reported a negative finding (144). The glutamine repeat polymorphism in NCOA3 
has also been investigated in multiple populations; however, most studies reported 
negative findings in terms of correlation between the repeat genotype and breast cancer 
risk (135,140).  
Two studies have reported an association of the variant G870A (rs603965) (146) in 
CCND1 with breast cancer risk (142,143), but other studies have reported negative 
results for this variant (136,141,144). A large-scale meta-analysis study (147) showed 
that the coding variant G870A increased breast cancer risk in Caucasians (OR=1.14, 
95%CI =1.01~1.28) (AA/AG vs. GG)) and than Asians (OR = 1.10, 95%CI (0.85, 1.42) ) 
based on 5,371 cases and 5,336 controls from seven case-control studies. However, 
another meta-analysis study (148) that investigated more than 11 case-control studies 
drew a different conclusion. The pooled analysis indicated that only homozygous 
carriers (AA) had elevated breast cancer risk (OR =1.082, 95%CI=1.005~1.165) in the 
Chinese population but no significant association was observed in the Caucasian 
population.  
Compared with breast cancer, very few studies have been conducted to investigate 
polymorphisms in ER cofactor genes with endometrial cancer risk. Kang etc (149) had 
firstly studied the variant of G870A in CCND1 among Korean women and found the AA 
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genotype to be associated with endometrial cancer risk. Later, Ashton (150) and his 
colleagues had verified such result in Australian women, and further, they found the 
increased risk is more relevant to patients with a family history of HNPCC(OR=2.95, 
95%CI (1.026-8.491)). However, a recent study (151) which investigated 9 cell cycle 
genes (including CCND1) and genotyped 1028 cases and 1003 controls did not confirm 
these associations in a Chinese population. 
Due to sample size limitation and the complexity of ER transcriptional regulation, the 
results from most of those publications are not consistent. Therefore, a large well-
designed study is warranted to further explore the association between genetic variants 
in ER cofactor and breast and endometrial cancer. 
7.5.3 Estrogen metabolism enzymes and ER cofactor genes 
are drug targets for breast and endometrial cancer 
treatments 
Current endocrine therapy for breast cancer has two approaches, namely the use of 
aromatase inhibitor (AI) and selective estrogen receptor modulator (SERM) (41). AI is 
used to block estrogen biosynthesis in postmenopausal patients; while SERM is used for 
long-term treatment to block estrogen-stimulated growth at the level of the ER in the 
tumor. Therefore, the alteration of estrogen metabolism and ER cofactor levels are 
closely related with prevention and treatment efficacy in hormonal driven cancers. 
AI has been proven to be an effective treatment for hormone-sensitve breast cancer in 
postmenopausal women.(152). Aromatase (CYP19) is the enzyme which plays a key role 
in the synthesis of  estrogen.  Two types of AIs are widely used in breast cancer 
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treatment, one is irreversible steroidal inhibitors which forms a permanent and 
deactivation bond with the aromatase enzyme; the other is non-steroidal inhibitors which 
inhibits the synthesis of estrogen via reversible competition for the aromastase 
enzyme(153). 
Tamoxifen is a traditional SERM and is the primary choice for anti-hormonal treatment 
in pre-menopausal patients and for ductal carcinoma in situ. It is also used for breast 
cancer prevention in premenopausal women at high risk. In terms of endometrial cancer 
and other side effects caused by tamoxifen, the development of raloxifene has 
encouraged the exploitation of the SERM concept (154). Studies of the cellular context 
and ER coactivator content have demonstrated the tissue-specific actions of tamoxifen 
and raloxifene in the endometrial carcinoma (53). In endometrial cancer cells, tamoxifen 
is an estrogen agonist which recruits coactivators rather than corepressors to gene sites; 
in contrast, tamoxifen recruits corepressors to the same gene site in breast cancer cells, 
where it acts as an estrogen antagonist. The evidence that receptor-tamoxifen complexes 
recruit more coactivators in endometrial cancer cells compared with breast cancer cells 
has advanced our understanding of the molecular basis for the tissue-specific effects, 
availability of specific cofactors and gene-selective activities of SERMs (53). Also, the 
type of interaction (tethered or DNA direct binding) and the expression levels of 
coregulators determine the distinct patterns of coregulator recruitment to the ligand-
receptor-gene assembly (9,53,155) (Figure7-8).  
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Figure7-8.  SERMs in the spotlight. 
Source: (155) 
Resistance to hormonal therapy is a common problem in the treatment of breast cancer 
patients. Schematic Figure7-9 (125) illustrates the three possible types of drug resistance 
to the tamoxifen. Metabolic resistance is due to polymorhphisms of metabolic gene 
CYP2D6 which could metabolize active tamoxifen to endoxifen. Around 10% of the 
population has CYP2D6 variants. The efficacy of tamoxifen could be reduced due to 
genetic variation in the metabolism pathway. Intrinsic resistance occurs due to high 
levels of membrane growth factor receptors (GFRs) which could target ER and 
coactivator NCOA3 for phosphorylation in PR negative tumors. Acquired resistance 
indicates that tumors initially respond to tamoxifen, but becomes less effective as GFR 
levels increase. Emerging data have also suggested that levels of ER cofactors play a 
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significant role in acquiring resistance to anti-estrogen action and genetic 
polymorphisms may play a role in the event (156). 
 
Figure7-9 The possible types of drug resistance to the SERMs. 
Source(125) 
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 8 Aims 
 
Given the established role of estrogens in the induction of breast and endometrial cancer, 
we surmised that common genetic variation in pathways of hormonal exposure and 
response may alter individual responses to endogenous estrogen and consequently 
modify hormonal-related cancer risk, which is based on the concept that heredity factors 
may play a role in carcinogenesis.  
We used the candidate gene based approach to systematically test DNA polymorphisms 
in 37 genes in the estrogen metabolism pathway and 60 ER-cofactor genes in three large 
case-control studies, namely the Swedish, Finnish and ECAC data sets, to ascertain 
whether the multiple genetic variants within the estrogen metabolic pathway and ER 
cofactor genes could modify the risk of breast and endometrial cancer or the risk of 
certain sub-phenotypes of breast cancer. Specifically, we have conducted the following 
three studies: 
Study I: Association analysis between common variation in estrogen metabolism genes 
and breast and endometrial cancer risk. 
Study II: Interaction analysis between ESR1 and ER cofactor genes and their effect on 
the risk of ER positive breast cancer. 
Study III: Association analysis between genetic variants in ER cofactor genes and 
endometrial cancer risk. 
The main objectives of these studies were:  
1. To identify genetic variants in Estrogen pathway and ER cofactors related to the 
risk of breast and endometrial cancer. 
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2. To ascertain whether the accumulated effect of multiple genetic variants within 
the estrogen metabolic pathway provides a more realistic determination of 
genetic effect than a single gene or single SNP approach.   
3. To determine whether the common variants in ER cofactor genes could alter 
individual response to endogenous estrogen and consequently modify receptor-
defined breast cancer risk. 
4. To reveal the effects of identified gene-gene interactions within ER cofactors on 
breast cancer risk. 
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 9 Study Populations 
 
The study populations of this thesis are based on three data sources: Swedish, Finnish 
and Endometrial Cancer Association Consortium (ECAC) sample sets (Table 9-1). 
Among them, the Swedish sample set comprised of both breast cancer and endometrial 
cancer samples. In study I and III, the discovery analysis was conducted in Swedish 
dataset, while the validation analysis was applied in Finnish dataset and ECAC dataset 
respectively. In study II, the association analysis was performed in Swedish and Finnish 
dataset separately and jointly.  
 
Table 9-1.  Summary of data sources used in each study. 










I √ √ √  
II √  √  
III   √   √ 
 
The studies were approved by the Institutional Review Boards in Sweden, Finland and 
the National University of Singapore, the National Health and Medical Research 
Council of Australia and the Wellcome Trust Case Control Consortium UK. All subjects 
provided written informed consent. 
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9.1 Swedish sample sets 
9.1.1 Parent Studies 
The Swedish sample set is a population-based case-control study with an emphasis on 
postmenopausal sporadic breast and endometrial cancer. The study base included all 
Swedish-born women between 50 and 74 years of age and resident in Sweden between 
October 1993 and March 1995 for breast cancer samples or between January 1994 and 
December 1995 for endometrial cancer samples (157-161). During these periods, all 
breast and endometrial cancer cases were identified at diagnosis through the six regional 
cancer registries in Sweden. Controls were randomly selected from the Swedish Registry 
of Total Population to match the cases in 5-year age strata. Most of the controls were 
shared between the breast and endometrial cancer studies (n=2633), but additional 
controls (n=735) were sampled after completion of the breast cancer study to match the 
recruitment period of the endometrial cancer study. 
Cases were asked to participate by their respective physicians. When patients consented, 
they received a mailed questionnaire asking for detailed information about intake of 
menopausal hormones, oral contraceptives, body mass index, reproductive history, 
medical history, and other lifestyle factors, which were listed on Table9-2. Controls 
were contacted with the same questionnaire via mail or telephone interview. In the 
endometrial cancer study, only women with an intact uterus were eligible as controls. 
The average interval from diagnosis to data collection was 4.3 months (Standard 
deviation=1.5months). Reasons for non-participation among cases and controls were 
mainly due to physicians’ refusal (psychiatric disorder, death, anxiety or poor health 
conditions), patients’ refusal or failure in contacting the woman.
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Table9-2. Selected characteristics distribution in the breast cancer and endometrial cancer analysis in Swedish postmenopausal women. 
Characteristic Breast cancer Endometrial cancer 
 
Number 
(case/ctrl) Mean  (case/ctrl) P value Number (case/ctrl) Mean  (case/ctrl) P value 
Age (years) 2818 /3111  63.4/63.3 <0.0001 802 /3550  64.1/63.4 0.0068 
Age at first full term birth 2373/2753 25.3 /24.6 <0.0001 685/3143 24.7 /24.6 0.61 
Age at menarche 2558/2832 13.5 / 13.6 0.012 732/3234 13.5 / 13.6 0.0089 
Age at last birth 2374/2751 30.1/30.4 0.05 684/3141 29.4 / 30.4 <0.0001 
Age at menopause 2818 / 3111 50.5/ 50.0 <0.0001 705 / 3304 51.0 / 50.1 <0.0001 
Parity 2818 / 3110 1.8/ 2.1 <0.0001 802/ 3548 1.89 / 2.14 <0.0001 
BMI (Recent)* 2802/ 3061 25.7 / 25.6 0.12 801 / 3504 27.4 / 25.4 <0.0001 
   Non-obese (BMI<30) 5113 24.5 (24.5, 24.6) NA 3685 24.5 (24.4, 24.6) NA 
   Obese (BMI≥30) 750 33.2 (32.9, 33.4) NA 620 33.8 (33.5, 34.2) NA 
  Case (%) Control (%)   Case (%) Control (%)   
Family history   <0.0001   <0.0001 
   No 2305 (84.0) 2366 (90.8)  681 (90.1) 2814 (95.1)  
   Yes 440 (16.0) 241(9.2)  75 (9.9) 146 (4.9)  
OC use   0.17   <0.0001 
  Never 1878 (69.4) 2125 (71.1)  616 (77.5) 2430 (69.0)  
  Ever 827 (30.6) 864 (28.9)  179 (22.5) 1094 (31.0)  
HRT use   <0.0001‡   <0.0001‡ 
  Never 1979 (72.7) 2468 (82.5)  573 (74.5) 2858 (83.4)  
  ET only 194 (7.1) 140 (4.7)  55 (7.2) 98 (2.9)  
  EPT 548 (20.1) 383 (12.8)  141 (18.3) 470 (13.7)  
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ET use   <0.0001   <0.0001 
  Never 1979 (91.1) 2468 (94.6)  573 (91.2) 2858 (96.7)  
  Ever 194 (8.9) 140 (5.4)  55 (8.8) 98 (3.3)  
EPT use   <0.0001   0.0001 
  Never 1979 (78.3) 2468 (86.6)  573 (80.3) 2858 (85.9)  
  Ever 548 (21.7) 383 (13.4)   141 (19.8) 470 (14.1)   
Obese†   0.0042   <0.0001 
   No 2407 (85.9) 2706 (88.4)  584 (72.9) 3101 (88.5)  
  Yes 395 (14.1) 355 (11.6)   217 (27.1) 403 (11.5)   
*weight/height2 
†obesity: BMI>=30 
‡Trend test P value 
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9.1.2 Present Studies 
9.1.2.1 Selection of present study populations 
For the breast cancer study, 1500 cases were randomly selected from parent study and 
contributed blood samples. 1500 controls with no previous malignancy were randomly 
selected and frequency-matched for age with the cases in the parent study. For the 
endometrial cancer study, all 802 cases were included and 802 age-frequency matched 
controls without previous malignancy were randomly selected from the parent study. 
Women with previous cancers were excluded in order to minimize the risk of including 
a metastasis from a previous cancer instead of an incident cancer. Cervical cancer in-situ 
and non-melanoma skin cancer should not metastatic and were therefore not excluded 
from present study. 
The initial purpose of the study was to examine the effect of menopausal hormone use or 
diabetes mellitus (158,162,163) on breast and endometrial cancer risk. In order to 
increase statistical power in subgroup analysis, all remaining 191 breast cancer cases, 
108 breast cancer controls and 277 endometrial cancer controls who had used 
menopausal hormones (estrogen alone or any combination of estrogen and progestin) for 
at least 4 years (breast cancer study) or at least 2 years (endometrial cancer study) were 
recruited into the present study. In addition, the remaining 110 breast cancer cases, 104 
breast cancer controls and 124 endometrial cancer controls with self-reported diabetes 
mellitus were also included in the present study. Since a large proportion of controls 
were shared between the studies, an additional 345 controls that had been selected for 
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the endometrial cancer study were added to the breast cancer study, and correspondingly, 
871 controls that had been selected for the breast cancer study were added to the 
endometrial cancer study. In total, 1801 cases and 2057 controls were invited to 
participate in the breast cancer project and 802 cases and 2074 controls in the 
endometrial cancer project. Table9-3 provides the details of participation rates and 
numbers in parent study and present study. 
9.1.2.2 Collection of biological samples 
All selected living women were contacted by mail and those who gave informed consent 
received a blood sampling kit by mail. Whole blood samples were drawn at a primary 
health care facility close to the women’s home and were sent back by mail. The majority 
of the samples arrived at Karolinska Institute within 24 hours after phlebotomy. All 
blood samples were immediately stored at -20оC.  For deceased cancer cases and those 
patients who declined to donate blood but consented to use of tissue, archival paraffin-
embedded, non-cancerous tissue samples (germ-line tissue samples) were collected. The 
main reason for non-participation was unwillingness or lack of time at the respective 
pathology department to provide the tissue blocks. In total, 1321 blood samples and 275 
tissue samples were obtained from breast cancer patients, and 603 blood samples and 
116 tissue samples were obtained from endometrial cancer patients. In addition, blood 
samples from 1524 breast cancer controls and 1574 endometrial cancer controls were 
obtained. Mean time for diagnosis of cases to arrival of the blood and tissue samples was 
5 years.  
In total, 1555 cases and 1518 controls passed quality control for genotyping in the breast 
cancer study. The final population-based participation rates in the study I were 73% 
(97%× 84% × 89%) and 60% (82%× 74% ×99%) in cases and controls respectively. In 
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study II and III, only blood DNA samples were used for genotyping. In total, 1257 (71%) 
cases and 1464 (58%) controls were successfully genotyped in the study II , and 564 
(64%) endometrial cancer cases and 1510 (61%) controls passed quality control for 
genotyping in the study III. 
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Table9-3 Participation rates in the breast and endometrial cancer sample sets in Sweden 
  Breast cancer  Endometrial cancer 
  Cases (%)a Controls (%)a Cases (%)a Controls (%)a 
Parent studies         
Eligible 3979 4188 1055 4216 
Participated 3345 (84%) 3454 (82%) 802 (76%) 3550 (84%) 
Present studies         
Eligible 2818b 3111b 802c 3550c 
Selected 1801 2057 802 2074 
Participated 1596 (89%)d 1524 (74%) 719 (90%) 1574 (76%) 
    Blood sample 1321 1524 603 1574 
    Paraffin Tissue sample 275 NA 116 NA 
Study I 1555 (97%) 1518 (99%) 564e (94%) 1510 (96%) 
Study II 1257e(95%) 1464 (96%) NA NA 
Study III NA NA 564e 1510 
a Percentages denote particpation rates where appropriate 
b  Pre-menopausal women and women with previous malignacies excluded 
c Women with previous maligancies excluded 
d Numbers included blood samples and archived paraffin tissue samples 
e Blood samples available only 
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9.1.2.3 Questionnaire information and risk factors collection 
The parent study questionnaire was extensive. For the present study, a number of risk 
factors were selected based on likelihood of being confounders or effect modifiers for 
any genotype-cancer association.  
Information on orally administered menopausal hormones in the present study was 
included. Conjugated estrogens, estradiol and other synthetic estrogens were classified 
as medium potency estrogens. Estriol was classified as low potency estrogen. Age at 
menarche and menopause were categorized into quartiles according to the distribution in 
the controls. Menopausal hormone use, age at first and last birth, parity, and body mass 
index were either categorized or used as continuous variables.Age was frequency 
matched in 5-year age-groups. Hormone receptor status information was retrieved from 
medical records of all participating breast cancer cases (Table9-2). 
Endometrial cancer can be divide into Type I endometriod tumours and Type II non-
endometriod tumours (papillary, squamous etc), where endometriod tumours constitute 
the majority of endometrial cancers (3,61). Endometroid tumours can be further divided 
according to cell differentiation (grade). Grade I tumours were defined well 
differentiated carcinomas (maximum 5% solid areas), grade II tumours were defined as 
moderately differentiated (6-50% solid areas) and grade III tumours were defined as 
poorly differentiated or entirely undifferentiated (more than 50% solid areas).  
9.2 Finnish sample set 
 The Finnish sample was from a hospital-based case–control study in which the cases 
consisted of two series of unselected breast cancer patients and additional familial 
patients diagnosed at the Helsinki University Central Hospital. The first consecutive 
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cases were 884 patients collected in 1997-1998 and 2000 which covers 79% of all newly 
diagnosed breast cancer cases during the collection periods (164,165).  The second 
consecutive, containing 986 newly diagnosed breast cancer patients, were collected in 
2001 – 2004 and covers 87% of all such patients during the collection period (166).  
Additional 538 familial breast cancer cases were also collected at the same hospital as 
described (167,168).  Women with a prior diagnosis of breast cancer in situ were 
excluded, leaving 2215 invasive breast cancer cases for analysis. 1287 healthy female 
population controls were collected from the same geographical regions of Finland as the 
cases.  
The data set in the Finnish study includes information on tumor histology, grade, age at 
the time of diagnosis, nodal status, TP53, progesterone receptor (PR) status and estrogen 
receptor (ER) status for majority of the cases. ER and PR status information were 
retrieved from medical records of all participants. The evaluation of the staining results 
was based on routine diagnostic criteria where samples were considered positive when 
10% of the cells were stained. The tumor characteristics were decribed in Table9-4.  
The risk factor information was not available for the Finnish controls. 
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Table9-4 Tumor characteristics of the cases of Swedish and Finnish breast cancer 
samples 
  Swedish Finnish 
  
Number of cases 
(Percent) 
Number of cases 
(Percent) 
ER positive 801 (78.6%) 1718 (80.8%) 
ER negative 218 (21.4%) 408 (19.2%) 
Postmenopausal 1245 (99%) 1174 (70.3%) 
Premenopausal – 498 (29.8%) 
Sporadic 1272 ( 83.8%) 1302 (59.3%) 
Familial 246 (16.2%) 895 (40.7%) 
 
9.3 ECAC sample set 
The validation data of study III were drawn from the 1st stage of GWAS data in 
endometrial cancer association consortium (ECAC). Detailed information about the 
samples is published elsewhere (169). In summary, the cases were from Australia (the 
Australian National Endometrial Cancer Study (ANECS) and the Newcastle 
Endometrial Cancer Study (NECS)) and from the UK (Studies of Epidemiology and 
Risk factors in Cancer Heredity (SEARCH)). The 599 ANECS participants were cases 
of incident primary cancer of the endometrium ascertained from state-based cancer 
registries between 2005 and 2007.  The NECS cases were from a hospital-based study, 
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from 1992 till 2005.  The 666 population-based SEARCH cases were diagnosed between 
2001 and 2007. 
Controls were genotyped as part of the Wellcome Trust Case Control Consortium 
(WTCCC) from England. These controls are composed from two sources: 2,694 controls 
from the 1958 Birth Cohort (1958BC), a population-based study in the United Kingdom 
of individuals born in 1 week in 1958; and 2,496 controls identified through the UK 
National Blood Service (NBS) (170).
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 10 Methodologies 
 
10.1 Candidate Gene and Tagging SNP Selection 
In study I, we selected 35 genes involved in estradiol or estrone metabolism and 
expressed in the breast based on the published literature. Given that the HapMap data 
had not been completed yet when project started, we selected 1007 SNPs from the 35 
genes and their 30kb flanking sequences from the dbSNP (build 124) and Celera 
databases, aiming for a marker density of at least one SNP per 5kb.  The SNPs were 
genotyped in 92 randomly selected Swedish control samples to assess LD pattern and 
coverage for tagging SNPs selection. Haplotypes were reconstructed using the PLEM 
algorithm (171) implemented in the tagSNPs program (172). A subset of SNPs, tagSNPs 
were chosen so that common SNP genotypes and haplotypes (frequency ≥0.03) were 
predicted with R2 ≥ 0.8 (173).  In total 302 tagging SNPs were selected for overall 
genotyping. 
In study II and III, the keywords ‘ER cofactor’, ‘ER coactivator’ and ‘ER corepressor’ 
were used in a literature search from PubMed to identify ER cofactor genes. In total, 60 
ER cofactor genes were identified as candidate genes. Tagging SNPs within the 60 
candidate genes were selected based on the HapMap CEU data (NCBI B36 assembly, 
dbSNP b126) (21). In brief, for each gene, all common SNPs with a MAF >0.05 within 
the gene and 5 kb surrounding region were first identified from the HapMap database 
(174). Tagging SNPs were then selected in Haploview version 4.1 (175) using a pair-
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wise SNP tagging approach with r2 >0.8 used as the criterion for selection. A total of 
806 tagging SNPs were selected for genotyping. 
10.2 Genotyping, quality control and other experiments 
10.2.1 Genotyping and quality control  
In study I, genotyping was performed using the Sequenom MassARRAY system 
(Table10-1). Of the 302 tagSNPs, 42 SNPs failed in the design stage of Sequenom 
genotyping assays. SNPs with a call rate < 85% (8 SNPs), MAF < 1% (9 SNPs) or out of 
Hardy–Weinberg equilibrium (HWE) with P<0.0002(0.05/252), (4 SNPs) were excluded 
from further analysis.  Overall, 239 tagSNPs out of selected SNPs were successfully 
genotyped. Details of the genes, number of SNPs used in analyses and coverage 
evaluation is summarized in Appendix 2.  
In study П and Ш, 790 SNPs were successfully designed on Illumina’s GoldenGate 
assay platform and subjected to genotyping analysis. SNPs with a call rate <96% and 
MAF<1% were excluded from further analysis. SNPs out of HWE with P < 7.4 x 10–5 
(0.05/675) were excluded. In total, 685 SNPs from the Swedish sample (study II and III) 
and 693 SNPs from the Finnish sample (study П) were used for statistical analysis, and 
675 shared SNPs between the Swedish and Finnish samples analyzed in the combined 
analysis (study П).  
In the three studies, all genotyping results were generated with positive and negative 
controls and checked by laboratory staff unaware of case-control status.  Genotyping 
was duplicated in 2% of samples (in both Swedish and Finnish samples) and there was 
concordance in >99% of the duplicated samples, suggesting high genotyping accuracy.  
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For the validation analysis in the study Ш, SNPs in the gene NCOA2, CREBBP, PRMT1, 
EP300 and CARM1 were drawn from the Illumina 610K panel based on the physical 
position of 5kb flanking specific gene regions. Cases were genotyped with Illumina 
Infinium 610K array and controls were genotyped using an Illumina Infinium 1.2M 
array (169) (Table10-1). The duplicate concordance was over than 99.9%. Cases and 
controls were restricted to the following criteria: the sex of all samples was confirmed to 
be female, the identity-by-descent analysis based on identity-by-state was conducted to 
detect first-degree cryptic relationships and related samples were excluded, the principle 
components analysis (PCA) was utilized to remove samples of non-European ancestry 
and all samples with a low or high heterozygosity (<0.65 or >0.68) or call rate <97% 
were excluded. A total of 1265 cases and 5190 controls were used for validation analysis.  
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Table10-1. Summary of the study sets and platforms used for genotyping. 
Study Analysis Source Cases Controls 
Genotyping 
platform 




Cancer Study 719 1730 
I Validation  
Finnish Breast Cancer 
Study 2245 1287 
Sequenom 
MassARRAY 
Swedish Breast Cancer 
Study 1257 1464 
II Joint analysis 
Finnish Breast Cancer 










Study 599  
Study of Epidemiology 
and Risk Factors in 
Cancer Heredity 666  Illumina 610K 
III Validation 
Wellcome Trust Case-
Control Consortium   5190 Illumina 1.2M 
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10.2.2 Reverse transcriptase-quantitative PCR analysis  
In study П, to verify the interaction between PPARGC1B and ESR1 functionally, our 
collaborators performed reverse transcriptase-quatititative PCR analysis (RT-PCR) for 
examining the PPARGC1B gene expression under estrogen stimulation. In brief, MCF-7 
cells were maintained in stripped serum for 72 hours for hormone depletion prior to 
hormone treatment, and were subsequently treated with 10nM 17β-estradiol for a period 
of 0 or 3 hours. Cells were then harvested and total RNA was extracted. 
Dimethylsulfoxide /vehicle-treated cells were used as controls for the same time course. 
Real-time PCR analysis was performed and the experiments were repeated at least twice. 
Two sets of primers were used for identifying different isoforms of PPARGC1B. The 
oligonucleotide sequences were as follows: PPARGC1B_1 isoform (NM_001172699.1) 
forward 5′-GAAGAGGAAGAAGGGGAGGA-3′ and reverse 5′-
CTCTGGTAGGGGCAGTGGT-3′; and PPARGC1B_2 isoform (NM_133263.3) 
forward 5′-CCTGAAGATGACGTGGGTCT-3′ and reverse 5′-
CCTTCCTTCTGGGTGTCAGA-3′. β-Actin specific primers (forward 5′-
TCCCTGGAGAAGAGCTACGA-3′ and reverse 5′-AGGAAGGAAGGCTGGAAGAG-
3′) were used as an internal control to normalize the amounts of reverse transcribed 
product used in the PCR reaction. Threshold cycle (Ct) values obtained for PPARGC1B 
isoforms were normalized to β-actin Ct values. The normalized threshold cycle (ΔCt) 
values were then used to calculate the difference (ΔΔCt) between estradiol-treated and 
dimethylsulfoxide-treated samples. The fold change of PPARGC1B was calculated as 2–
ΔΔCt. 
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10.3 Statistical Analysis 
10.3.1 Single SNP association analysis 
To assess the risk association between SNPs and breast / endometrial cancer risk, per-
allele odds ratio (ORs) (assuming a log-additive model) and 95% confidence intervals 
were estimated using a logistic regression. The Cochran-Armitage trend test was 
performed to calculate P values for each of the SNPs in the three studies. We used a 
Bonferroni correction to adjust for multiple testing, although this is conservertive as not 
all of the tests are independent.  
In study II, forward stepwise logistic regression was used to explore whether the 
associations at the SNPs were independent from each other. The selection criterion was 
P <0.2. The analysis was performed in ER-positive breast cancer risk in the two sample 
sets separately as well as in the combined ER-positive sample dataset. To account for 
different MAF in the two populations, a binary indicator variable for study was included 
in the regression models in addition to age in the combined data regression analysis. 
10.3.2 Meta-analysis 
Inverse variance weighting was used in a meta-analysis for combining independent 
datasets. In study П, as Swedish cases and controls were age-matched, the individual OR 
was obtained from age-unadjusted analysis in the Swedish sample and age-adjusted 
analysis in the Finnish sample. To evaluate differences in ORs between studies, a test of 
heterogeneity was carried out for each individual SNP analysis. In study III, a Cochran–
Mantel–Haenszel test was applied to test genotype-phenotype association in the 
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combined samples by treating the discovery samples and validation samples as 
independent studies. The Breslow-Day test and Cochran’s Q test were performed to 
evaluate the significance of heterogeneity among individual studies. 
10.3.3 Interaction analysis 
In study II, pair-wise interaction analysis was performed under a dominant mode of 
inheritance using logistic regression and likelihood ratio tests. To maximize the 
statistical power, we pooled sample sets from the Swedish and Finnish data. Age and 
study were included in the model as covariates. The full model included an interaction 
term between the two interacting variables for the risk of breast cancer. In this 
multivariate logistic regression analysis, each coefficient provided an estimate of the log 
OR whilst adjusting for all other variables included in the model. Likelihood ratio tests, 
comparing models with and without the interaction term, were used to generate 
interaction P values. 
10.3.4 Admixture maximum likelihood (AML) test  
One approach for assessing the departure of the distribution of the Cochran-Armitage 
test statistics from the global null distribution (no SNPs associated) is the AML test, as 
described by Tyrer et. al. (176) which has been used in analysis in studies I and III,. 
Briefly, the software for the AML test assesses the experiment-wise significance by 
examining the empirical distribution of single marker test statistics based on a ‘‘pseudo-
likelihood ratio’’ test, comparing the ratio of values of the optimized likelihoods under 
the null and alternative hypotheses for the observed data, with the corresponding values 
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obtained from datasets with case-control status permuted randomly. The method is based 
upon fitting a mixture model to the distribution of the test statistics with two components, 
one representing SNPs which are independent of the case-control status, the other 
representing SNPs associated with case-control status. In order to determine whether 
there exists a cumulative effect from multiple variants, the Cochran-Armitage test 
statistics for the associated SNPs are assumed to all have the same non-centrality 
parameter value (chi-squared). The common effect size of the associated SNPs within 
the complex is also estimated though the non-centrality parameter. 
In study I, we performed the AML-based global test of association for the full metabolic 
pathway as well as for 3 sub-pathways.  In addition, we performed gene-specific 
analyses, using the AML-based global test on SNPs within genes, within the androgen-
estrogen conversion sub-pathway.  We also carried out AML tests adjusted for a non-
genetic risk factor which was based on comparing models fitted to the distribution of 
likelihood ratio test statistic values obtained from fitting logistic regression models (for 
case-control status) with (i) only the risk factor (for adjustment) entered as covariate and 
with (ii) the SNP genotype and the risk factor entered as covariates. In study III, we 
performed the AML-based global test of association for the 5 complexes, 3 sub-
complexes and gene-specific analysis in Swedish population, as well as for NCOA2 sub-
complex in the validation analysis.  
10.3.5 Imputation analysis 
In study III, imputation analysis for SNPs in NCOA2 (Chr8: 71181-71484 kbp) and 
CREBBP (Chr16: 3720-3875 kbp) were performed. We imputed the two regions in the 
two datasets: 2074 Swedish samples and 6455 validation samples, by using their 
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genotyped SNPs whose genotypes all passed the QC thresholds (call rate >90%, MAF 
>1%, HWE P>10-6 in controls). The imputation was performed by using the combined 
reference panel, 1000 Genomes(177) + HapMap III (178) reference data (CEU data) in a 
single imputation analysis. Imputed genotypes with probability less than 90% were 
excluded; and SNPs with impute information scores less than 80%, MAF less than 1%, 
HWE P < 0.0001 in controls and missing rate greater than 10% of genotypes were 
dropped from further analysis. Association testing was performed in PLINK (179) by 
using Cochran-Armitage trend test to analyze the genotype–phenotype association in 
both studies.  
 
SNP association analyses were performed using STATA version 8.0 (StataCorp, College 
station, TX, USA). Linkage disequilibrium (LD) calculation was performed in 
Haploview version 4.1(175). The AML analysis was performed using a software 
obtained from the authors of the method (176). The software Quanto version 1.2.3 was 
used for power estimation (180). The software IMPUTE version 2(181,182) was used 
for imputing genotype data of untyped SNPs. 
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 11 Study I 
 
Estrogen exposure is critical for the onset and progression of both breast and 
endometrial cancers and represents the most well-established common risk factor for 
both diseases. Genetic variation of the genes involved in estrogen metabolism has, 
however, not been consistently associated with these two cancers. We posit that this is 
due to the complexity of multiple moderate genetic effects within the pathway, 
inadequate study design and analytical methodology to detect these effects. In order to 
determine this, we genotyped 239 tagSNPs from 34 metabolic genes in 1596 breast 
cancer cases, 719 endometrial cancer cases and 1730 controls from Sweden and further 
validated 120 tagSNPs in 2245 breast cancer cases and 1287 controls from Finland. In 
addition, we applied the AML-based global test to examine the cumulative effect from 
multiple SNPs within a pathway or sub-pathway. 
11.1 Results 
First, we performed single SNP association analysis in the Swedish population. Of the 
239 tagSNPs analyzed (Methodologies section 5.2.1 and Appendix 2), 17 SNPs (7.1%) 
had p-values less than 0.05 for breast cancer, and 18 SNPs (7.5%) had p-values less than 
0.05 for endometrial cancer. For breast cancer, the smallest p-value was 0.00034 at 
rs7167936 within CYP19A1, and for endometrial cancer, the smallest p-value was 
0.00017 at rs12595627 in CYP19A1.  The single-SNP associations were moderate and 
did not survive Bonferroni correction for multiple testing.  However, the Q-Q plot 
showed a deviation from the null distribution of no association (Figure11-1), indicating 
that the observed p values of several top SNPs are smaller than expected by chance.  
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Therefore, single-SNP associations were suggestive, but instead of any single variant 
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Figure11-1  –log10 Q-Q p-value plots from single SNP trend tests of 239 SNPs in the estrogen metabolism pathway 
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We next sought to evaluate the cumulative effect from multiple variants.  To do so, we 
employed the AML method that assesses the experiment-wide significance of 
association by analyzing multiple SNPs through a global test.  The whole metabolic 
pathway can be sub-divided into three a priori defined sub-pathways, each performing a 
specific metabolic function, which we showed the schematic in Chapter 2 (Figure12-6).   
Sub-pathway 1 is involved in the synthesis of androgen, sub-pathway 2 is involved in 
the conversion of androgens to estrogens, and sub-pathway 3 is responsible for removing 
estrogens. To investigate whether there is multi-SNP association for the whole pathway 
and whether any of the three sub-pathways is particularly important in influencing 
disease risk, we performed the progressive pathway-based global test on the whole 
metabolic pathway as well as the three sub-pathways using the AML method. The global 
test yielded marginally significant association for the whole metabolic pathway in both 
breast (Pglobal=0.034) and endometrial (Pglobal =0.052) cancers (Table11-1).  Dividing the 
metabolic pathway into three functional sub-pathways for the global test revealed strong 
association between the androgen-to-estrogen conversion sub-pathway and both breast 
(Pglobal =0.008) and endometrial (Pglobal=0.014) cancers. The association evidence 
survived correction for performing 4 pathway-based tests in each cancer (Pglobal 
corrected=0.032 for breast and 0.056 for endometrial).  In contrast, the other two sub-
pathways showed no association with either form of cancer.  
To validate the association in the androgen-to-estrogen conversion sub-pathway, we 
genotyped the 120 SNPs of this sub-pathway in Finland sample set and performed the 
same AML analysis. The validation analysis in the Finnish sample revealed similar 
association between the androgen-to-estrogen conversion sub-pathway and breast cancer 
(Pglobal=0.015) (Table11-1). 
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Table11-1   P values of the global tests of genetic association between the SNPs in the 
estrogen metabolic pathways and Breast/Endometrial cancer risk. 





















Whole Pathway      (239 
SNPs) 0.034 0.052 --  
Androgen Synthesis (11 
SNPs) 0.397 0.381 --  
Androgen-Estrogen 
Conversion       (120 SNPs)* 0.008 0.014 0.015 0.001 
Estrogen Removal  (144 
SNPs)* 0.172 0.385 --   
P-values were based on 2500 permutations. 
*:36 SNPs are overlapped. 
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In view that hormone-related risk factors may play a differential role in breast cancer 
subtypes, we also investigated the association in the androgen-to-estrogen conversion 
sub-pathway in hormone-related breast tumor subtypes. As surrogate markers for 
hormone driven tumor subtypes we constructed variables as combinations of 
menopausal status, family history and estrogen receptor (ER) status. We compared 
subgroups of patients, defined on values of these variables, with controls, in terms of 
their genotype distributions. The sub-group results showed that in both Swedish and 
Finnish samples, significant association was observed in postmenopausal patients 
(Pglobal=0.008 and 0.018 respectively), postmenopausal patients without family history 
(Pglobal =0.001 and 0.04 respectively), and postmenopausal patients with estrogen 
receptor positive (ER+) tumors (Pglobal =0.0006 and 0.05 respectively) (Table11-2).   It 
was striking that no significant association was observed in either premenopausal 
patients or postmenopausal patients with family history or estrogen receptor negative 
(ER-) tumors.  
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Table11-2 Patient subgroup analysis of the androgen-to-estrogen conversion sub-pathway 
  All Cases Menopausal Status Family History ER Status 
   Pre Post (PM) PM Familial PM Sporadic (PMS) PMS ER+ PMS ER- 
# controls 1518       
# cases 1555 − 1545 244 1260 661 183 
Swedish Sample 
Pglobal 0.008 − 0.009 0.23 0.001 0.0006 0.65 
# controls 1287       
# cases 2245 498 1176 313 853 704 137 
Finnish Sample 
Pglobal 0.015 0.10 0.018 0.43 0.040 0.050 0.36 
# controls 2805       
# cases 3800 498 2721 557 2113 1365 320 
Joint AML 
Analysis 
Pglobal 0.001 0.10 0.002 0.33 0.0005 0.0003 0.57 
All the Pglobal values are based on 5000 permutations and reflect comparisons of various patient subgroups with all the controls. 
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In an attempt to refine the association within the androgen-to-estrogen conversion sub-
pathway, we performed a gene-based AML analysis in the combined Swedish/Finnish 
breast cancer sample and the Swedish endometrial cancer sample.  Among the 15 genes 
tested (Table11-3), strong association was observed for CYP19A1 with both breast 
(Pglobal =0.003) and endometrial (Pglobal =0.006) cancers and UGT2B4 (Pglobal =0.002) 
with breast cancer only. The associations in breast cancer survived correction for 
multiple testing of 15 genes (Pglobal =0.045 for CYP19A1and 0.03 for UGT2B4). We also 
observed suggestive association for UGT2B11 in breast and endometrial cancer as well 
as HSD11B1, SULT2A1 and SULT2B1 in breast cancer. Consistent with the pathway-
based associations, the gene-based associations are generally more significant in 
sporadic postmenopausal patient samples than in the whole breast cancer sample (except 
SULT2B1). Furthermore, the importance of CYP19A1 and UGT2B4 in breast cancer risk 
is supported by an exclusion analysis showing that the exclusion of either gene from the 
global test of the sub-pathway will reduce the global significance of association for the 
sub-pathway from 0.0015 to 0.011 for CYP19A1 or to 0.010 for UGT2B4. Meanwhile, 
the fact that the association for the sub-pathway remains significant (P<0.05) in the 
exclusion analysis suggests that, although CYP19A1 and UGT2B4 are the major players, 
genetic variation within other genes in the sub-pathway also contributes to the 
association.  
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Table11-3 Gene-based AML Pglobal values for the 15 genes within the androgen-to-
estrogen Conversion sub-pathway. 
Genes # SNPs Breast Cancer * Endometrial 
  All Cases PMS PMS ER+ Cancer 
AKR1C4 11 0.121 0.098 0.113 0.729 
CYP11B1 2 0.595 0.692 0.619 0.663 
CYP11B2 4 0.390 0.496 0.665 0.863 
CYP19A1 15 0.006 0.003 0.013 0.006 
HSD11B1 9 0.181 0.125 0.026 0.701 
HSD11B2 6 0.130 0.244 0.096 0.778 
HSD3B1 7 0.549 0.551 0.108 0.065 
SRD5A1 5 0.870 0.852 0.851 0.325 
SRD5A2 7 0.267 0.151 0.190 0.265 
STS 9 0.393 0.582 0.997 0.806 
SULT2A1 8 0.332 0.040 0.080 0.535 
SULT2B1 12 0.028 0.190 0.193 0.784 
UGT1A1-9 12 0.378 0.413 0.205 0.888 
UGT2B11 7 0.179 0.078 0.027 0.047 
UGT2B4 7 0.002 0.003 0.003 0.31 
*:PMS, Postmenopausal Sporadic Cases;  PMS ER+, Postmenopausal Sporadic Cases 
with ER+ tumors; the AML Pglobal values for breast cancer were based on both the 
Swedish and Finnish samples and calculated using Fisher’s method.  All AML Pglobal 
values are based on 5000 permutations. 
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11.2 Findings and implications 
Our pathway-based multi-SNP association analysis revealed a significant association 
between genetic variants in the androgen-to-estrogen conversion sub-pathway and risk 
of two hormone-dependent cancers, particularly ER+, sporadic breast cancer. Single 
SNP analysis did not reveal a similar association. The finding is consistent with the 
previous study where the AML-based multi-SNP analysis was shown to be more 
powerful than single SNP tests in yielding significant and consistent association, when 
the genetic risk is carried by multiple risk alleles each with moderate effect (183).  
An association study of nine candidate gene groups (involving 120 candidate genes) was 
performed in breast cancer by using the same AML approach, and interestingly, only the 
group of eight genes involved in the steroid hormone signalling were significantly 
associated (118). Our study has moved one step further by highlighting that the power of 
the pathway-based association analysis can be further increased when the analysis is 
guided by well-defined biological information. Unless one enzyme is the rate limiting 
step for the entire metabolic pathway, it is not likely that small functional perturbations 
of individual variants would have a major impact on the overall effect of the metabolic 
pathway.  To test the hypothesis that several genetic variants, each conferring weak to 
moderate effects, contribute to overall genetic risk, we adopted a systematic pathway-
based approach for association analysis by testing the joint effect of multiple genetic 
variants in a progressive fashion from the whole metabolic pathway to biochemical sub-
pathways and further down to individual genes.  Such a progressive approach allows us 
to not only establish consistent association in three cancer samples from two different 
populations but also refine the association to androgen-to-estrogen conversion 
component of the metabolic pathway.  Our study has therefore advanced our 
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understanding on the role of the estrogen metabolism in breast and endometrial cancers 
by 1) removing the ambiguity surrounding the genetic association results and 2) 
indicating the androgen-to-estrogen conversion to be the important component of the 
metabolic pathway in modulating the risk and thus to be the focus of future studies.     
After menopause, ovarian estrogen production dramatically declines and conversion of 
adrenal androgens to estrogens in peripheral tissues becomes the major source of 
circulating estrogens. The final step of this conversion is catalyzed by aromatase, 
encoded by CYP19A1 (183).  Thus, there is biological plausibility in the association 
between CYP19A1 polymorphisms and postmenopausal breast cancer.  Moreover, 
pharmacological inhibition of aromatase prevents recurrences in postmenopausal women 
with ER+ breast cancer and new contralateral primaries (184), which has challenged the 
previous routine of a 5-year course of tamoxifen alone (185). Our study has advanced 
our understanding of CYP19A1 by suggesting that the modulation of aromatase activity 
by either germline variation or pharmacological agents can influence the development of 
ER+ tumor in postmenopausal women. Furthermore, the convergence of genetic and 
pharmacological effects of CYP19A1 also raises therapeutic possibilities. Moreover, 
other genes implicated by our genetic study, such as UGT2B4, might also be 
pharmacological targets for treating breast cancer.    
Hormone exposure is a common risk factor for breast and endometrial cancer. Our 
employment of the three samples of two different hormone-related cancers from two 
different populations allowed us to apply a very stringent criterion for declaring an 
association.  Furthermore, our breast cancer subgroup analysis has demonstrated that the 
genetic determinants within the androgen-to-estrogen conversion sub-pathway play a 
more prominent role in postmenopausal women with sporadic ER+ tumors.   Our study 
demonstrated that the modulation of hormone exposure by genetic variation has a 
  83 
differential impact on breast tumor subtypes. Endogenous sex hormone level has been 
shown to be associated with breast cancer risk in postmenopausal women (186), and 
particularly with the risk of ER+/PR+ breast tumors (187). The effect of hormone-
related factors on breast cancer risk apparently differs by ER status (188) and 
menopause status (189,190).  It could also differ by the status of having a positive family 
history of the disease, as suggested by a recent study showing that most cases of 
hereditary breast cancer are probably not related to cumulative hormone exposure (191). 
Our findings have therefore advanced the development of a general model for breast 
cancer risk: hormonal factors, both genetic and reproductive, play a key role in the 
genesis of post-menopausal and “sporadic” breast cancer, whereas genes involved in 
DNA repair, checkpoints, and genetic stability (such as BRCA1, BRCA2, p53, ATM, 
CHK2) appear to be more involved predominantly in breast cancers associated with 
family history of disease.   
It is worth noting that the contribution of genetic polymorphisms to risk is a function of 
both their prevalence and penetrance and thus the relative importance of individual 
SNPs may vary from population to population.  More studies in different populations are 
needed to fully understand the role of the androgen-to-estrogen conversion sub-pathway 
in breast cancer.  We would also like to highlight that our results are of genetic 
association in nature, and functional variants causally linked to cancer risk remain to be 
identified.  
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 12 Study II 
 
Estrogen exposure is a major risk factor for breast cancer, and the estrogen receptor (ER) 
plays an important role in mediating cellular response to estrogen exposure. ER positive 
breast tumor patients could benefit from endocrine therapy through attenuation of ER 
activity, such as by tamoxifen treatment. ER cofactors, including both co-activators and 
co-repressors, can alter ER activity and consequently modify ER-mediated cellular 
response to estrogen exposure. We therefore posited that genetic variation within ER 
cofactors may influence ER-mediated cellular response to estrogen and thus the risk of 
developing hormonal breast cancer. To test the hypothesis, we carried out a candidate 
gene based association analysis in 1257 cases and 1464 controls from Sweden and in 
2215 cases and 1265 controls from Finland to investigate the impact of DNA 
polymorphisms within 60 ER cofactor genes on the development of breast cancer, 
particularly hormonal ER positive breast cancer.   
12.1 Results 
We investigated two independent case–control samples of breast cancer from Sweden 
and Finland. First, we performed single SNP association analyses using trend tests in the 
Swedish and Finnish samples separately by stratifying the cases into ER-positive and 
ER-negative groups, with 685 SNPs being tested in the Swedish sample and 693 SNPs 
being tested in the Finnish sample (Methodologies section 5.2.1, and Appendix 3). 48 
SNPs (7.00%) in the Swedish sample and 50 SNPs (7.28%) in the Finnish sample 
showed association with ER-positive breast cancer risk with nominal P <0.05 . Seven 
SNPs showed consistent association between the two independent samples, and six of 
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them were located within the PPARGC1B gene (Table12-1). In contrast, no overlapping 
SNPs showed consistent associations with ER-negative breast cancer between the two 
independent samples. We also evaluated the SNP association with overall breast cancer 
risk. Only two SNPs showed consistent association between the two independent 
samples (Table12-1), and none of the associations survived Bonferroni correction for 
multiple testing in the combined samples (smallest Pcorrected = 0.198).  
We then analyzed SNP associations in the combined Swedish and Finnish samples 
through inverse-variance meta-analysis. In general, SNPs showed stronger evidence of 
association with ER-positive breast cancer than ER-negative breast cancer. The most 
significant association was identified at rs741581 within the second intron of 
PPARGC1B (OR = 1.41, P = 4.84 x 10–5) in ER-positive breast cancer, which survived 
the Bonferroni correction for multiple testing (Pcorrected = 0.03). rs741581 was one of the 
seven SNPs that showed consistent associations between the Swedish and Finnish 
samples.  
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Table12-1  ORs and P values of the consistent SNPs between the Swedish and Finnish samples from the analyses of ER+ and overall 
breast cancer. 









PPARGC1B rs741581 chr5:149182978 1.266 (1.019,1.573) 0.034 1.662 (1.279,2.16) 4.06E-5 
PPARGC1B rs6895698 chr5:149120455 1.183 (1.017,1.375) 0.032 1.273 (1.087,1.492) 0.002 
PPARGC1B rs1012543 chr5:149157138 1.215 (1.054,1.401) 0.008 1.231 (1.066,1.422) 0.005 
PPARGC1B rs4705365 chr5:149093146 1.196 (1.026,1.394) 0.024 1.190 (1.014,1.397) 0.029 
PPARGC1B rs2340621 chr5:149122509 1.203 (1.05,1.378) 0.008 1.100 (0.965,1.254) 0.037 
CCND1 rs649392 chr11:69173974 0.873 (0.766,0.995) 0.042 0.881 (0.779,0.998) 0.043 
ER+ PPARGC1B rs10036538 chr5:149135781 1.158 (1.004,1.336) 0.048 1.153 (0.996,1.334) 0.048 
CARM1 rs1529711 chr19:10884434 1.178 (1.02,1.362) 0.026 1.225 (1.062,1.413) 0.006 
overall RBM23 rs7469 chr14:22440037 1.213 (1.013,1.451) 0.037 1.273 (1.086,1.493) 0.006 
*: Odds ratio and corresponding 95% confidence interval which is allele-based test. OR from individual study was calculated based on 
age-unadjusted in Swedish and age-adjusted in Finnish. 
†: P-value of association using CA trend-test (rounded to 3 decimals) 
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To have a better understanding of the associations within PPARGC1B, we performed 
genotype-based association analyses by assuming dominant, recessive and additive 
models of inheritance. We found that the top three SNPs yielded the most significant 
association evidence in the dominant model compared with other models. Under the 
dominant model, the same six SNPs (as for the trend tests) of the genotyped 40 tagSNPs 
within PPARGC1B showed consistent association with ER-positive breast cancer 
between the Swedish and Finnish samples (Table12-2). The strength of the association 
(ORs) at the six SNPs was stronger in ER-positive breast cancer than in overall or ER-
negative cancers, with the strongest association identified at rs741581. The six SNPs 
were located within two regions of high LD (Figure12-1B,C), suggesting that the 
associations at those SNPs may not be completely independent. We therefore performed 
a forward stepwise logistic regression and revealed two independent associations with 
ER-positive breast cancer at rs741581 (P = 0.031) and rs6895698 (P = 0.014) in the 
combined sample. Under the dominant model, we found that rs741581, rs6895698, age 
and study sample were four independent variables associated with ER-positive breast 
cancer risk. Similarly, the same stepwise analysis of ER-positive breast cancer in the two 
individual samples separately also revealed two independent associations at rs741581 (P 
= 0.172) and rs2340621 (P = 0.036) in the Swedish sample and at rs741581 (P = 0.023) 
and rs6895698 (P = 0.053) in the Finnish sample. Notably, rs6895698 and rs2340621 lie 
within the same LD block and are highly correlated (r2 = 0.72, according to HapMap 
CEU data) (Figure12-1).  
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Table12-2  Six overlapping SNPs in PPARGC1B associated with ER positive breast 
cancer in Swedish and Finnish samples.  
Swedish Finnish 
SNP ID Allele§ 
  
Subtype MAF† OR‡ (95%CI) MAF† OR‡ (95%CI) 
rs4705365 G/A ER+ 1.26 (1.05,1.52) 1.26 (1.05,1.52) 
  ER- 1.14 (0.81,1.61) 1.17 (0.9,1.52) 
    All cases 0.21 1.14 (0.97,1.33) 0.17 1.18 (0.99,1.4) 
rs6895698 G/A ER+ 1.27 (1.06,1.53) 1.39 (1.15,1.67) 
  ER- 1.05 (0.74,1.48) 1.14 (0.88,1.49) 
    All cases 0.22 1.12 (0.96,1.3) 0.17 1.25 (1.05,1.49) 
rs2340621 G/A ER+ 1.3 (1.08,1.57) 1.22 (1.03,1.46) 
  ER- 0.86 (0.61,1.2) 1.05 (0.82,1.34) 
    All cases 0.31 1.12 (0.96,1.31) 0.32 1.14 (0.97,1.34) 
rs10036538 C/G ER+ 1.19 (0.99,1.42) 1.2 (1,1.43) 
  ER- 0.91 (0.65,1.28) 1.05 (0.81,1.35) 
    All cases 0.26 1.03 (0.89,1.2) 0.22 1.11 (0.94,1.31) 
rs1012543 A/G ER+ 1.26 (1.05,1.51) 1.26 (1.06,1.5) 
  ER- 1.08 (0.77,1.51) 1.08 (0.84,1.38) 
    All cases 0.26 1.11 (0.95,1.29) 0.23 1.18 (1,1.39) 
rs741581 G/A ER+ 1.32 (1.05,1.67) 1.76 (1.33,2.31) 
  ER- 0.81 (0.49,1.32) 1.21 (0.81,1.82) 
    All cases 0.08 1.12 (0.92,1.37) 0.05 1.53 (1.18,1.98) 
§Major allele / Minor allele. 
† Minor Allele Frequency (MAF) was from control samples only. 
‡ Odds Ratios were performed on dominant model based, which were age-unadjusted in 
Swedish and age-adjusted in Finnish. 
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Table12-3.  Association analysis of rs7761846 within ESR1 under dominant model in 
ER+ cases analysis. 
  Control Case OR (95%CI) Pvalue 
Swedish 1442 675 1.43 (1.10, 1.86) 0.007 
Finnish 1246 1669 1.10 (0.81, 1.48) 0.55 
Combined* 2688 2344 1.28 (1.05, 1.56) 0.014 
*: Combined analysis was performed on logistic regression adjusted by age and study. 
 
Our previous study in the same Swedish sample suggested that polymorphisms in a 
region within ESR1 are associated with breast cancer risk (80,192). Using the haplotype 
information from the HapMap CEU data, we identified a common SNP rs7761846 
having high correlation (r2 = 0.89) with the haploype within the region. The SNP 
rs7761846 was therefore genotyped in the Swedish and Finnish samples. Given that a 
large association study of ESR1 by the Breast Cancer Association Consortium also 
revealed a significant association within the same region under a dominant model (193), 
we performed a genotype-based association analysis under a dominant model of 
inheritance. As expected, rs7761846 showed association with ER-positive breast cancer 
(OR = 1.28, P = 0.014) in the combined sample (Table12-3). 
Given the known modification of ER activity by PPARGC1B in cellular response to 
estrogen exposure, we investigated the genetic interaction between rs741581, rs2340621 
and rs6895698 within PPARGC1B and rs7761846 within ESR1 in terms of modulating 
ER-positive breast cancer risk. The analysis in the combined sample identified a 
significant synergistic interaction between rs2340621 (representing PPARGC1B) and 
  90 
rs7761846 (representing ESR1) (Pinteraction = 0.008) (Table12-4). Women carrying both 
PPARGC1B (rs2340621) and ESR1 (rs7761846) risk genotypes (GA/AA and CT/CC 
respectively) had a much higher risk for breast cancer than noncarriers (GG and TT) (OR 
= 1.94, P = 2.03 x 10–6). However, significant genetic interactions could not be detected 
in overall or ER-negative breast cancer. 
To understand the molecular mechanism underlying the observed genetic interaction, we 
investigated whether there was any transcriptional cross-talk between the two genes 
beyond the known ligand-dependent, co-activating interaction of the PGC-1β with ERα 
(194,195), using the ER-responsive MCF7 breast cancer cell line. 
First, we examined the expression of PPARGC1B in MCF7 and noted a twofold 
induction of PPARGC1B expression by ER activation after estradiol administration 
(Figure12-2). As a marker of transcriptional activity, chromatin immunoprecipitation-
sequencing analysis in the same MCF7 cell line identified a significant peak of RNA 
polymerase II occupancy close to the transcriptional start site of PPARGC1B within the 
LD region of SNP association, and the RNA polymerase II occupancy was further 
enhanced by estradiol treatment. This observation confirms the transcriptional 
responsiveness of PPARGC1B to estradiol (196). Moreover, the chromatin 
immunoprecipitation-sequencing analysis also identified five ER binding sites in and 
around the LD region of significant association with ER-positive breast cancer 
(Figure12-1F,H). Interestingly, the sites showing highest signals of ER occupancy were 
seen at two locations, one ~13 kb from the significant SNP rs741581 and the second 
within 31 kb 3′ of the polyadenylation signal sequence. Furthermore, our data indicated 
that all of the ER binding sites around PPARGC1B were engaged in chromatin loop 
formation centered on the PPARGC1B gene (Figure12-1I), which indicates that ERα 
directly regulates PPARGC1B. 
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Taken together, these data strongly indicate that PPARGC1B expression could be 
directly regulated by ERα and – when coupled with the known enhancement of ERα 
transcriptional activity by the PGC-1β at the site of binding – suggest a feed-forward 
regulatory loop between the two genes that augments ER signaling when the two factors 
are present.
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Table12-4 Analysis of pair-wise interaction between SNPs within PPARGC1B and ESR1 on the ER+ breast cancer in the combined 
Swedish and Finnish samples under dominant model. 
ESR1 
(rs7761846) PPARGC1B  
Genotype GG (rs2340621) GA/AA (rs2340621) 
  case (%) ctrl (%) OR(95%CI) case(%) ctrl(%) OR(95%CI) 
TT 916 (39) 1121 (42) 1 1160 (50) 1280 (48) 1.18 (1.03, 1.34) 
CT/CC 106 (5) 151 (6) 0.95 (0.71, 1.29) 161 (7) 134 (5) 1.94 (1.47, 2.55) 
Interaction 
P value* 0.008 
  GG (rs6895698) GA/AA (rs6895698) 
 case (%) ctrl (%) OR(95%CI) case(%) ctrl(%) OR(95%CI) 
TT 1284 (55) 1566 (58) 1 791 (34) 837 (31) 1.28 (1.11, 1.47) 
CT/CC 160 (7) 184 (7) 1.21 (0.93, 1.55) 106 (5) 101 (4) 1.77 (1.30, 2.42) 
Interaction 
P value* 0.506 
  GG (rs741581) GA/AA (rs741581) 
 case (%) ctrl (%) OR(95%CI) case(%) ctrl(%) OR(95%CI) 
TT 1741 (74) 2076 (77) 1 335 (14) 326 (12) 1.41 (1.17, 1.70) 
CT/CC 225 (10) 251 (9) 1.25 (1.01, 1.55) 42 (2) 34 (1) 2.18 (1.32, 3.59) 
Interaction 
P value* 0.459 
*: Analysis was performed on combined data set, in which study and age were regarded as covariables. 
. 
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Figure12-1 Transcriptional regulation of PPARGC1B by ERα in MCF7 cell line  
Figure Legends: From top to bottom, A. Schematic diagram of the genes from UCSC database; B. Map 
positions of six significant SNPs within PPARGC1B; C. Recombination rate surrounding PPARGC1B 
from HapMAP CEU database; D. MCF7 input DNA density for CHIP-seq analysis; E. CHIP-seq RNA 
PolII occupancy density without E2 treatment; F. CHIP-seq ER occupancy without E2 treatment; G. 
CHIP-seq RNA PolII occupancy density with E2 treatment; H. CHIP-seq ER occupancy with E2 
treatment; I. ER interaction loop detected by ChIA-PET 
(196)
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12.2  Findings and implications 
In this study, we investigated the association between common variation within ER 
cofactor genes (36 ER co-activators and 24 ER co-repressors) and the risk of breast 
cancer. The utilization of two independent case–control samples of northern European 
ancestry has allowed us to identify an association based not only on the overall 
significance in the large combined sample, but also on the consistency of the SNP 
association between the two individual samples. We found significant associations 
between PPARGC1B polymorphisms and risk for ER-positive breast cancer and 
revealed a synergistic effect between genetic polymorphisms within PPARGC1B and 
ESR1. 
Genetic association studies of ER cofactor genes have so far been limited. Wirtenberger 
and colleagues investigated the coding variant Ala203Pro of PPARGC1B and found it to 
be associated with familial breast cancer susceptibility (197). The Ala203Pro (rs7732671) 
variant of PPARGC1B, however, is 10 kb away and not correlated with PPARGC1B 
SNP rs741581 (r2 <0.05 in HapMap CEU data), and thus would not have been detected 
by our tagging SNP approach. Nevertheless, both Wirtenberger and colleagues’ study 
and our study support the association of genetic variation of PPARGC1B with particular 
subtypes of breast cancer.  
Importantly, the association of PPARGC1B as well as its synergistic interaction with 
ESR1 was only observed in breast cancer patients with ER-positive tumors, as would be 
expected according to the biochemical mechanism of interaction. There is growing 
evidence that the impact of genetic risk factors on breast cancer varies by hormone 
receptor status. For example, recent studies by the Breast cancer association consortium 
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(BCAC) have led to the discovery of novel breast cancer susceptibility loci in FGFR2, 
TNRC9, 8q24, 2q35, and 5p12 that showed stronger association with ER-positive 
disease than with ER-negative disease (18,28,29,198), with fibroblast growth factor 
receptor also being a direct target of ER. These data suggest the risk of ER-positive 
tumors, that has been shown to be driven by reproductive factors in epidemiologic 
studies, also has a genomic basis based on the constituents of the ER gene regulatory 
network (199,200). In our study, although the sample sizes of the two ER-positive 
datasets were smaller compared with the two overall datasets, the number of singnificant 
overlapping SNPs between the Swedish and Finnish studies was thus larger than that 
observed in the overall breast cancer analysis.  
The genetic interaction between PPARGC1B and ESR1 is biologically plausible. The 
PPARGC1B protein PGC-1β is a bona fide ER co-activator (194) that physically 
interacts with ERα and plays a role in amplifying ER signaling, which provides a 
convincing biological mechanism for the observed genetic interaction between the two 
genes. Furthermore, our series of transcriptional regulation analyses in the MCF7 ER-
positive breast cancer cell line has demonstrated that PPARGC1B expression can be 
induced by estrogen treatment, and this transcriptional response of PPARGC1B is 
probably mediated by five functional ER binding sites around PPARGC1B that are all 
engaged in interlocking chromatin loops highly indicative of an ER-regulated gene (196). 
PPARGC1B may thus be involved in a feed-forward control mechanism with ERα such 
that ER induction (for example, by estradiol treatment) heightens the expression of a co-
activator PPARGC1B of ER, which in turn increases ER action at the DNA binding site. 
The feed-forward looping mechanism may therefore further augment the protein 
interactions between PPARGC1B and ESR1.  
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There are some limitations in our study.  
1. The coverage of common variation is lower (less than 80%) for some genes 
(Appendix 3), such that some associations may have been missed. In addition, we have 
only selected tagging SNPs within 5kb of surrounding sequences of each candidate 
genes and regulatory SNPs located further away from the genes, such as the one reported 
within ESR1(27) have not been evaluated.  
2. Limited power as a result of small sample size for the ER-negative patients may have 
led to the non-significant results in ER-negative analysis. Some of the top SNPs for each 
individual sample set may be false positive, resulting in the small overlap between the 
numbers of significant SNPs in both datasets.  
3. There exists a certain degree of phenotypic heterogeneity in terms of ER status 
definition. In the Swedish sample set, ER-positive tumor was defined as having more 
than 10fmol receptor/mg protein in an immunoassay approach (201), while in the 
Finnish sample set, an ER-positive tumor was defined as having more than 10% cell 
nuclei staining positive in an Immunohistochemistry (IHC) method(202).  
4. The definition for ER status varies over time (current ER-positive tumor definition is 
> 1% cell staining(69)), such that inconsistent definition in the two sample sets may lead 
to misclassification in the ER-negative tumor group. If there were certain SNPs 
specifically associated with ER-negative tumors other than ER-positive tumors, the 
misclassification could bias the result towards the null.  
The latter two points may reduce the sample size of the ER-positive subjects, but is not 
expected to affect the homogeneity within the ER-positive subgroup. 
In general, our study has revealed an association of genetic variation within PPARGC1B 
with the risk of ER-positive breast cancer. Consistent with the known interaction of 
PPARGC1B and ER at the molecular level, where PPARGC1B modulates ER activity 
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and thus ER signaling, our study revealed a synergistic effect between genetic variation 
within the PPARGC1B and ESR1 genes. PPARGC1B has been shown to alter responses 
to the selective ER modulator, tamoxifen (195). Kressler and colleagues also 
demonstrated that PPARGC1B indirectly co-activates tamoxifen-bound ERα, which 
cooperates with NCOA1 to enable tamoxifen agonism in kidney and osteosarcoma cell 
lines. Lastly, the synergism demonstrated in the present study also suggests that 
disrupting the interaction between an ER co-activator – such as PPARGC1B – and ERα, 
or blocking their mutual activation, may represent a sensitive and leveraged strategy for 
cancer prevention (203).  
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 13 Study III 
 
Given that estrogen receptor (ER) transcription regulation activity is modulated by its 
biochemical cofactors, genetic variation within ER cofactor genes or complexes may 
alter cellular response to estrogen exposure and consequently modify the risk for 
endometrial cancer. We genotyped 685 tagging SNPs within 60 ER cofactor genes in 
564 endometrial cancer cases and 1,510 controls from Sweden, and tested their 
associations with the risk of endometrial cancer. We investigated the associations of 
individual SNPs by trend tests as well as multiple SNPs within a gene or gene complex 
by multi-variant association analysis. No significant association was observed for any 
individual SNPs or genes, but possible association of the cumulative genetic variation of 
the NCOA2 complex as a whole (NCOA2, CARM1, CREBBP, PRMT1 and EP300) with 
endometrial cancer risk was observed (Padjusted=0.033). However, the association was not 
validated in an independent European dataset of 1265 cases and 5190 controls. The 
results indicate that the genetic variants within ER cofactor genes have no significant 
effect on endometrial cancer risk in the European population. 
13.1 Results 
13.1.1 Discovery analysis 
A total of 564 cases and 1510 controls were included in the discovery analysis, which 
was described in Chapter 5 above (Table10-1). All the cases and controls were 
postmenopausal Swedish women. We successfully genotyped 685 tag SNPs within the 
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60 ER cofactor genes, which can capture 2410 common SNPs (MAF>5%) with an 
average coverage (r2 > 0.8) of 91%. Out of these, 51 genes had coverage over 80%. 
Details of the SNP coverage evaluation is summarized in Appendix 3. 
Of the 685 tag SNPs analyzed, nominal P values of less than 0.05 were observed at 42 
SNPs (6.13%). The Q-Q plot of the observed p-values from the association tests is 
shown in Figure13-1, with no clear deviation from the null. The most significant 
association was observed at SNP rs130052 (MAF=0.13) within the CREBBP gene (odds 
ratio (OR) = 1.41 (95% CI 1.16-1.72), age-adjusted P =0.002). The ORs with or without 
age-adjustment were similar. No P-values of individual SNPs could, however, survive 
the Bonforroni correction for multiple testing. 
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Figure13-1. QQ plots for trend test of 685 ER cofactor SNPs associated with 
endometrial cancer risk in the Swedish population. 


































We further evaluated the association of genetic variants within each individual ER 
cofactor gene by carrying out multiple variant association analysis through the 
Admixture Maximum Likelihood (AML) test.  We found evidence of association at four 
genes, CREBBP (P=0.017), NEDD4 (P=0.030), NCOA2 (P=0.037) and NR0B1 (P=0.031) 
with nominal P values < 0.05 (Table13-1). However, after correction for multiple testing, 
none of the associations remained significantly associated with endometrial cancer risk. 
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Table13-1 Top four most significant genes associated with endometrial cancer risk in the 
Swedish population 
Function Gene(alias) Chr SNP# P-value+ P-value‡ 
Coactivator CREBBP 16 18 0.017 0.00046 
Coactivator NEDD4 15 34 0.03 0.0066 
Coactivator NCOA2  8 27 0.037 0.0051 
Corepressor NROB1 X 9 0.031 0.014 
+: P value is based on 5000 permutations in AML test for the specific gene. 
‡: P value of most significant SNP in the specific gene. 
 
In view of ER cofactor genes playing their roles via protein complexes, we investigated 
the associations of the five ER cofactor complexes using AML, namely the P160 family 
related histone acetylation & methylation complexes (containing CARM1, PRMT1, 
CREBBP , EP300, NCOA1, NCOA2 and NCOA3), the RNA processing complex 
(PPARGC1A, PPARGC1B and SRA), the Pol II recruitment complex (MED13 and PBP), 
the ligand-dependent corepressors (NRIP1 and LCoR) and the histone deacetylases 
complex (HDAC7 and NCoR1). Among the five complexes, the P160 family related 
histone acetylation and methylation complex showed evidence of association 
(Poverall=0.023), but the association could not survive the correction for testing five 
independent complex groups (Poverall=0.115) (Table13-2).   
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Table13-2. Global P values of AML tests for genetic association between the tag SNPs 
in the ER cofactor complexes and endometrial cancer risk in the Swedish population. 






CREBBP 18 Histone acetylation 
& methylation EP300 10 0.023 
PPARGC1A 46 
PPARGC1B 41 
RNA processing SRA1 5 0.674 
MED13 6 
Pol II recruitment PBP 4 0.318 
NRIP1 9 
Ligand-dependent 
corepressors LCoR 5 0.586 
HDAC7 10 
Histone deacetylase NCoR1 3 0.576 
 P-values were based on 5000 permutations 
 
As the three individual P160 histone acetylation & methylation complexes (NCOA1, 
NCOA2 and NCOA3) play distinct roles in transcriptional regulation, we further 
investigated the associations of these sub-complexes using the AML test. While the 
NCOA1 and NCOA3 sub-complexes did not show association, the NCOA2 sub-complex 
showed a significant association (Poverall=0.011) with endometrial cancer risk, which 
remained significant after correction for testing three sub-complexes (Poverall=0.033) 
(Table13-3).  
 
  104 
 
Table13-3. Sub-complex AML tests for genetic association between the tag SNPs in the 
histone acetylation & methylation and endometrial cancer risk in the Swedish population.
  















NCOA3 complex EP300 10 0.067 
 
 
13.1.2  Validation study in GWAS 
As genetic variants in the NCOA2 sub-complex demonstrated significant association 
with endometrial cancer risk in the Swedish population, we attempt to validate the result 
in an independent European dataset of 1265 endometrial cancer cases and 5190 controls 
for which GWAS genotyping data is available (169). We extracted SNPs from the 
Illumina Infinium 610K array panel located within 5kb flanking the five genes of the 
sub-complex. In total, 65 SNPs were identified and 53 SNPs passed quality control. The 
coverage of common SNPs is 96% on NCOA2 gene, 86% on CREBBP gene, 80% on 
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CARM1 gene, 50% on EP300 and 20% on PRMT1. The AML test was applied on each 
of the five genes and the whole sub-complex (Table13-4), but none of them showed 
significant association (P=0.71 for the sub-complex). 
The high coverage of genotyped SNPs allowed us to perform imputation analysis on the 
two genes, NCOA2 and CREBBP in both the Swedish and GWAS sample sets.  A total 
of 19 SNPs on CREBBP and 270 SNPs on NCOA2 were shared between the two datasets. 
We performed a meta-analysis of the results for these SNPs across the two datasets. 
However, no SNP, gene or complex was found to be significantly associated with the 
risk of endometrial cancer. 
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Table13-4. Sub-complex AML test for genetic association between the tag SNPs in the 
NCOA2 complex and endometrial cancer risk in the validation analysis.  
 
Sub-complex Gene ID #tagSNP 
Gene- based Ptrend Complex-based 
Ptrend 
CARM1 4 0.116 
PRMT1 3 0.516 
NCOA2 26 0.822 
CREBBP 15 0.469 
NCOA2 complex EP300 5 0.373 0.707 
 
13.2 Findings and implications 
To our knowledge, this is the first comprehensive analysis of the association between the 
polymorphisms of ER cofactor genes and endometrial cancer risk. We did not find 
significant association between single SNPs or individual genes associated with 
endometrial cancer risk. Although the genetic variation of the NCOA2 complex as a 
whole is marginally associated with endometrial cancer risk in the Swedish population, 
we failed to validate this finding in an independent study of subjects of European 
ancestry.  
Perissi and Rosenfeld (131) described a vast number of  coregulator-complexes that are 
engaged in ER mediated transcriptional regulation with various functions and enzymatic 
activities. P160 coactivators are well-known to bind directly to hormone-activated 
estrogen receptors and recruit secondary coactivators (131,204), where the CREBBP and 
the CARM1 interaction domain physically overlap with the related transferable 
activation domains of the p160 family member(133). A study conducted by Lee and 
colleagues demonstrated that NCOA2, CARM1 and EP300 or CREBBP form a ternary 
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complex that could enhance estrogen receptor (ER) function in a synergistic manner 
(205). Although the discovery analysis demonstrated that the cumulative effects of 
multiple variants of the NCOA2 complex have a possible contribution to the risk of 
endometrial cancer, the association failed to be replicated in an independent sample.  
It has been reported (206,207) that ER coactivators are more commonly expressed in 
ER-positive endometrial cancer or well-differentiated, hormone-related endometrial 
cancer rather than ER-negative endometrial cancer. It is therefore likely that the ER 
cofactors regulate estrogen binding to the estrogen receptors in ER-positive endometrial 
cancer. Unfortunately, we were unable to perform the sub-group analysis due to sample 
size limitation and ER status information deficiency.  
The current study provided a comprehensive analysis of common genetic variants within 
the ER cofactor genes.  First, the selection of a large number of tag SNPs enabled 91% 
of common variation (MAF>5%) within the 60 candidate genes to be captured in the 
association analysis. Furthermore, imputation analysis was performed in the discovery 
and validation samples to evaluate additional untyped SNPs and to ensure the same set 
of polymorphisms to be analyzed in the discovery and replication samples. With our 
present sample size with 1829 cases and 6700 controls, our study had an overall power 
of 85% at a significance level of 0.05 to detect a causal allele with MAF\0.1 and OR\1.2 
for endometrial cancer. However, we have not found any evidence of association, 
whether the association was evaluated by using individual SNPs or the genes/complex 
based test.   Therefore, our results suggest that common polymorphisms within these 
genes do not play a significant role in overall endometrial cancer risk in the European 
population. Further studies will be needed to examine if common variants with weaker 
effect or rare variants within these genes may play a role in influencing endometrial 
cancer risk.  
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 14 General Discussion 
 
14.1 Study Design 
In this thesis, we used case-control studies to examine the association between genetic 
polymorphisms and risk of hormone-driven cancers.  Compared with cohort studies, the 
case-control approach is more suited to genetic epidemiology for a few reasons: firstly, 
given that cohort studies need to wait for a “sufficient” number of disease events to 
occur, the case-control approach is more practical for uncommon diseases with long 
induction / latent period, such as cancers and many chronic diseases; secondly, it can 
provide an opportunity to do analysis on multiple genes, along with other risk factors 
and to search for gene-gene, gene-environment interactions; thirdly, unlike biological 
markers of exposure, genetic markers are more stable indicators of host susceptibility. 
Therefore, case-control studies are more efficient in relatively short time periods, 
provide greater statistical power and allow for the comprehensive analysis of multiple 
genetic and environmental factors. 
14.2 Precision and Validity 
The design strategies of epidemiological studies are intended to improve precision and 
validity in measurements through reducing the sources of random and systematic errors.  
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14.2.1 Precision and random error 
14.2.1.1 Genotyping misclassification 
Genotyping misclassification is one of most common random errors that diminish 
precision in genetic association studies. It may stem from several possible reasons: a) 
measurement device, whereby each genotyping platform has a certain intrinsic 
genotyping error rate; b) low quality DNA samples, or having some DNA samples 
contaminated by other samples; c) human errors, such as experiments not being 
optimized, sample mix-ups and reagents being used incorrectly and wrong interpretation 
of genotyping results; d) sporadic mutations at probe binding sites. In general, 
genotyping misclassification is non-differential and unpredictable.  To reduce possible 
errors, we took a few precautionary measures. Robust genotyping platforms (Sequenom 
and Illumina) and stringent quality control criteria were applied. If the overall SNP call 
rate across all samples is less than 85% (Study I with Sequenom Mass Array system) or 
90% (Study II & III with Illumina’s GoldenGate platform), the SNP will be excluded 
from analysis; similarly, if sample call rate is less than 96%, the sample will be excluded 
from analysis. In instances where the specific SNP call rate was 80-85% for the 
Sequenom system or 90–95% for the Illumina platform, the clustering of genotype calls 
was re-evaluated by an independent observer. Only SNPs with sufficiently good 
clustering were  included. In addition, 2% of the samples were duplicated on plates and 
the concordance rate was found to be over 99%. Designing of primers, probes, assay 
conditions and allele scoring were conducted in the Sequenom platform and Illumina’s 
GoldenGate assay system respectively.  
 
  110 
14.2.1.2 Sample size and statistical power 
To increase the precision of a study, there are generally two approaches: one is to 
enlarge the sample size, which is a primary way to reduce sampling error, and another to 
increase the statistical efficiency. 
Given that both type I and type II errors need to be reduced, power for genetic 
association studies will depend upon a few factors, such as sample size, the effect size of 
the causal locus, the strength of LD between causal allele and marker, the frequencies of 
causal alleles and the disease models. Figure14-1 (208) depicts the trend of sample sizes 
needed in different scenarios given a fixed OR =1.5, power=80% and type I error 
probability (α). At α =0.05, more than 900 samples (450 cases / 450 controls) are needed 
to detect a common SNP (MAF=0.05) under a dominant inheritance, while at the α 
=0.005, more than 1500 samples are needed. However, larger sample sizes are needed to 
detect the same common SNP under the recessive model. At the same time, testing 
multiple SNPs in genetic association studies requires correction by reducing α, thus a 
large sample size will be necessary to improve statistical power in certain scenarios(209). 
Since nearly a hundred genes have been studied in our project and the genetic effect of 
most genes was unknown, a one to one ratio between cases and controls has been 
applied in our Swedish samples to improve the statistical efficiency. 
 
 








































Figure14-1 Sample size estimates for case-control analysis of SNPs in different 
scenarios 
(OR =1.5; Power =80%; α=type I error rate; Disease baseline risk=10E-5  
Adapted from (208) 
14.2.2 Validity 
Validity has two components: internal validity and external validity (210). Internal 
validity is dependent on the amount of error in measurements, including exposure, 
disease status, and the associations between these variables. Good internal validity 
implies a lack of selection bias, information bias and confounders in data measurements 
and suggests that inferences may be drawn as they pertain to the subjects of the source 
population. External validity is also called generalizability,which indicates the 
inferences are valid among people outside study population. 
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14.2.2.1 Selection bias and information bias 
It is well-known that case-control studies are more prone to bias than cohort studies in 
terms of selection bias and recall bias, as the study base is often not well-defined and the 
information on environmental exposure is often collected retrospectively. Also, it can be 
difficult to establish a clear temporal relationship between the exposure and the disease 
because of the retrospective nature of the data. Thus it was initially thought that case-
control studies are not valid as cohort studies (211) . This idea has changed in the last 
couple of decades since researchers realized that well-designed case-control studies can 
be just as efficient  as cohort studies if efforts were made to minimize selection bias and 
improve validity.  
In our Swedish parent study, the cases are a representative sample of all breast cancer 
cases identified through six regional cancer registries nation-wide in Sweden, whilethe 
controls are sampled directly from the Swedish Registry of Total Population 
representing the general population from which the cases were drawn from. Moreover, 
the present cases were chosen by random sampling from all cases of the parent study, 
which may help to reduce sampling errors. In the selection of controls, an age frequency 
matching approach was also used to reduce selection bias. This sample set is not only 
suitable for a genetic epidemiology study, but also could be used for a classical 
epidemiology study, thus it is also suitable for gene-environment interaction study. 
The Finnish sample set is a hospital-based case-control study, in which the cases 
consisted of two series of unselected breast cancer patients and the controls are healthy 
women from the same geographical regions as the cases in Finland. As the exposure we 
investigated is genotype, the distribution of genotypes is usually unknown to both the 
participants and investigators, therefore the likelihood of selection bias is reduced. In 
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addition, as genotype is unlikely to be modified by reproductive factors and BMI (212), 
confounding is less likely to occur. Therefore, a case-control study design could make 
the estimation of the relationship between genotype and disease more valid and efficient. 
The high percentage of familial breast cancer in Finnish cases may cause selection bias. 
If a particular genetic variant has significant association with overall breast cancer and 
stronger association with familial breast cancer, the oversampling of familial breast 
cancer cases may cause a overestimation of the genetic effect size for overall breast 
cancer. Such an impact can be minimized by stratified analysis where the association 
analysis is performed adjusting for breast cancer subtypes. 
In the ECAC analysis, the differences in allele frequencies may be observed when 
analyzing UK control with Australian cases, either due to confounding when different 
ancestries carry different disease risk, or due to control sampling effects. This may result 
in false positive findings. In the first WTCCC publication(213), the authors examined 58 
samples to make sure the patterns of linkage disequilibrium in the WTCCC control 
samples are identical to those in HapMap CEU data. The controls had been carefully 
examined and subjects of non-European ancestry have been removed.  As Australian 
cases were also of European ancestry, the genetic backgrounds of subjects in the two 
groups are expected to be similar. The λGC from the previous publication (169), in which 
the same sample set (1st stage of GWAS) was used in our validation sample set was 
shown to be small (1.04) and the PCA plots indicated that confounding due to 
population stratification is relatively low. Besides, given that no significant findings 
were identified in the validation study, the chance for false positive discovery is low. 
Therefore, we expect that the controls in the validation study are adequently well-
matched to our cases. 
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To eliminate selection bias during our experiment, DNA samples from cases and 
controls were randomly assigned to the plates carrying positive and negative controls, 
and all genotyping results were generated and checked by laboratory staff unaware of 
the case–control status. 
 
14.2.2.2 Confounding 
A crucial consideration in genetic studies is confounders. Race or ethnicity can be an 
important confounder in any population-based study of complex diseases. Disease 
prevalence often changes with geography and ethnic origin, and allele frequencies of 
SNPs can vary widely throughout the world. Additionally, variation in LD between 
populations of different origins may lead to differences in haplotypes and tagging SNP 
selections. Therefore, population stratification is often the most common confounding in 
genetic association studies. It may result from recent admixture or from choosing poorly 
matched cases and controls (214). Given that a confounding could mask the true genetic 
effect, it should be removed in the study design and analysis.  
The best strategy for correcting population stratification is to use genetically matched 
cases and controls. Therefore, geographic matching has often been used for genetic 
matching. However, due to some unknown population substructures, geographic 
matching may not always work. One method to examine the genetic matching is to do a 
genomic control (GC) correction, which is a relatively nonparametric method for 
controlling the inflation of test statistics. This can be done by  genotyping of random 
panels of SNPs to assess population structure. If cases and controls are not well-
matched, the λgc measure can be used to correct the inflation. Another way to correct for 
population stratification is to do a principal components analysis (PCA), which 
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compares the principal components of genotyping data of the samples against those of 
reference samples of known ethnicities. Therefore, the correction is specific to a genetic 
variation with substantial differences in alleles frequencies across reference ancestral 
populations.  In contrast to correcting for λgc which is a inflation factor assumed 
constant across all random (null association) SNPs, correcting for PCs can be viewed as 
an alternative way of controlling inflation using locus specific factors (215). 
To assess the possible influence of population stratification in the estrogen metabolism 
study (Study I ), we used λgc to estimate inflation. Half of the Swedish and Finnish 
subjects have been analyzed in a published GWAS study (216), where λgc were 
estimated to be 1.01 and 1.02 respectively. Furthermore, PCA plots using GWAS SNP 
data suggested that the samples were homogeneous within each population (217). In the 
study of the association between ER cofactor SNPs and endometrial cancer risk (Study 
III), we employed an independent sample set for validation. Since the controls were 
from the UK and the cases were from two areas of Australia and UK, we searched for 
λGC from the original publications (169). The λGC was shown to be small (1.04) and the 
PCA plots indicated that the population was homogeneous.  
In the study of ER cofactor associated with breast cancer (Study II), , we have stratified 
the analysis by population for the single genetic association analysis. On one hand, this 
facilitates the comparison between the Swedish and Finnish cases and controls in 
different or similar population groups; on the other hand, this helps to identify any 
heterogeneity between the two populations due to the genetic architecture, i.e. 
differences in allele frequency and LD pattern, as well as disease prevalence. The 
number of overlapping significant SNPs between the two individual datasets is small for 
both ER-positive and overall breast cancer analyses. This may indicate ethnic 
heterogeneity exists in the two population samples. Another way to deal with population 
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stratification is to adjust for population in a multivariate analysis when the relationship 
between the exposure and outcome is in the same direction between population groups. 
Therefore, to assess gene-gene interaction in a multivariate logistic regression model 
which required a larger sample size, we specified the population as a categorical variable 
for adjustment in the combined data set.  
14.2.2.3 External validity 
It is well-recognized that large sample sizes, rigorous p-value significance thresholds, 
and replication in multiple independent samples are necessary for reliable results. Thus, 
reproducibility is deemed as one important feature of a good genetic association study 
and replication is widely used to assess external validity. Several reasons may cause the 
study to lack reproducibility, such as small sample sizes, biological and phenotypic 
complexity, differences in LD patterns between populations, population stratification, 
sub-population heterogeneity in study design and differences in analytical methods. In 
reality, due to the heterogeneity of both genetic and environmental determinants of 
disease, it is difficult to replicate gene-gene interactions or gene-environment 
interactions in the study of multiple disease-predisposing alleles with modest effects on 
complex human diseases, since the power of the study is reduced and the observed 
effects are dependent on the measure of association (i.e multiplicative scale vs. additive 
scale) 
Since the early 1990’s, most breast cancer genetic studies have been focused on putative 
functional variants in candidate genes. However, few susceptibility genes have been 
identified and verified by follow-up studies. There are two possible reasons: a) the 
number of possible genetic polymorphisms is large for a common complex disease, but 
the effect size of each polymorphism is moderate and b) the prior probability that any 
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polymorphism will be associated with disease is low, and most polymorphisms that 
achieve a modest level of statistical significance are false positives (type I errors). The 
false-positive rate can be reduced by setting more stringent threshold for declaring 
statistical significance. However, most studies lack the statistical power to detect 
moderate relative risks at stringent levels of statistical significance.  
Figure14-2 illustrates several replication scenarios. The best scenario for replication is 
that the same genetic markers are significantly associated in the follow-up study as those 
in the initial study, or different genetic markers but in the same LD block are 
significantly associated in the follow-up study. The second best scenario for replication 
is where the same genetic markers are not significantly associated with the disease in the 
follow-up study but the same direction of effect was observed as that in the original 
study. However, if the same genetic markers are examined in both studies, but are shown 
to have opposite effects, this may imply that the initial finding was a false discovery, or 
that different phenotypes (due to different definition) were examined in the initial and 
follow-up studies. Allelic heterogeneity and genetic pleiotropy may also account for 
non-replication of the initial findings.  
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In the estrogen metabolism study (Study I), to replicate the findings in the Swedish 
population, we performed external validation in the Finnish data as an independent 
sample set. The initial study was a global test, where we examined whether there are any 
true associations between sub-pathway and breast cancer risk. Although we could not 
refine which specific SNPs are associated with the risk for overall / subgroup breast 
cancer due to the moderate effects of single variants and thus could not achieve the gold-
standard for replication (218) (i.e. by replicating the association with precisely the same 
genetic variant in an independent sample), the results of our study may reflect the nature 
of associations between polymorphisms and a complex disease in studies of moderate 
sample sizes. 
In general, the Breast Cancer Association Consortium (BCAC) study provides a good 
sample for external validation for several reasons: 1) The large sample size provides 
good statistical power to detect modest associations between genetic determinants and 
breast cancer risk, and the follow-up of tentative associations through large replication 
studies will facilitate the robust identification of additional true susceptibility loci 
(120,219); 2) It enables well-powered analyses of  homogenous subgroups (such as 
pathological and clinical subgroups, ER positive and ER negative breast cancer) 
(18,198); 3) Multiple populations collected by individual institutes across European 
could help to refine the location of the causal variants based on different sizes of LD 
blocks through haplotype-based analysis (22); 4) Comprehensive phenotypic 
information available in this study provides the potential to investigate the modifiable 
effects of reproductive factors or hormone-related factors on genetic susceptibility, or to 
test for effects of gene-gene interaction on breast cancer risk (212).  
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14.3 Effect modification 
Another important theme of genetic epidemiology is effect modification, also known as 
heterogeneity of effects among different groups. Therefore, a simple measurement of the 
association between a genotype and disease may mask the effects of biological 
interactions between the genotype and other risk factors. However, if a large number of 
possible interacting factors are tested simultaneously, the opportunities for type I 
statistical errors increase, and even more stringent levels of statistical significance are 
required for declaring significant association in an interaction analysis. The power to 
detect a modest interaction effect will be extremely small. Thus, careful selection of the 
exposure of interest and the genetic variants will be needed in assessing possible 
interactions. 
In study II, interaction was detected between polymorphisms of ESR1 and PPARGC1B. 
We performed the interaction test based on several reasons: a) biological studies indicate 
that  the estrogen receptor (ERα) protein functionally interacts with the ER cofactor 
protein (PPARGC1B); b) the specific interaction sites on ESR1 (AF2 domain) and 
PPARGC1B (LXXLLmotif) have been identified by other studies (194,195) ; c) we have 
demonstrated that a synergistic interaction loop exists between the two genes in a 
biological study (196) ; d) lastly, significant associations at the two polymorphisms have 
been established in both our previous (80)and current study. 
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14.4 Polymorphisms in estrogen related genes and recent 
findings in GWAS 
In contrast to the candidate gene approach which specifically test one or several to 
hundreds genetic variants selected based on a prior hypothesis, a genome-wide 
association study (GWAS) investigates all or most of the genes by analyzing more than 
1 million SNPs across the genome in hundreds to thousands of individuals from a 
particular population to identify susceptibility loci of a specific phenotype. The approach 
is therefore termed as “hypothesis-free”.  
Peng et al (220) did a comparison of all the SNPs identified by meta-analyses, pooled 
analyses based on the candidate gene approach and GWAS in the beginning of 2011. 
With the false-positive report probability (FPRP) method (221), 10 of 145 breast cancer 
susceptibility variants were shown noteworthy at a prior probability of 0.001 and 
sufficient statistical power to detect an OR of 1.5 in a meta-analysis or pooled analysis 
based on the candidate gene approach. Interestingly, a polymorphism in the CYP19 gene, 
which encodes the enzyme that converts testosterone to estradiol, has been confirmed to 
be significantly associated with breast cancer risk. In contrast, among 25 reported SNPs 
in GWAS (before 2011), only three SNPs overlap with the ten significant SNPs 
identified by meta- or pooled analyses of candidate gene studies. However, no variant in 
CYP19 has been reported in GWAS analysis. The small overlap between associated 
SNPs identified by GWAS and candidate gene studies may indicate that many of 
findings from candidate gene studies are likely false discoveries.  
 
  122 
To further examine the polymorphisms of estrogen reated genes identified in GWAS, I 
searched for the original breast cancer GWAS studies using the filter from National 
Human Genome Research Institute (NHGRI) GWAS catalog (website 
http://www.genome.gov), where GWAS publications were screened from all studies 
published in English on PubMed till April 2012. The details of GWAS, satisfying the 
following criteria are listed in the Appendix 4: “a. inclusion of at least 100,000 SNPs in 
the initial stage, before quality control filters are applied, and b. statistical significance 
(SNP-trait p-value <1.0 x 10-8) in the overall (initial GWAS + replication) population” 
(222).  Among the 17 papers, 40 SNPs have been identified and 23 loci have been 
reported to associate with breast cancer risk. Interestingly, one locus (223) is located 
downstream of the nuclear receptor-interacting protein1 (NRIP1) gene. NRIP1 is one of 
the ER cofactor genes and the encoded protein acts as a strong transcriptional repressor 
for estrogen receptor (224). Molecular biological studies demonstrated that the 
expression of NRIP1 is significantly higher in ER positive tumors relative to ER 
negative ones with P<0.0001, and that blocking of NRIP1 could induce the cell 
proliferation in an ER positive tumor cell line (225,226). In addition, one locus, 6q25.1 
located near ESR1, which encodes as estrogen receptor α., has been reported by two 
GWAS (27,227).  
 
Compared with the candidate gene approach, GWAS are effective in identifying results 
that are consistent and replicable. The contribution of GWAS to our understanding of 
the genetic susceptibility to breast cancer is important. However, if sufficient SNPs from 
specific genes have been selected for evaluation, the candidate gene approach could also 
have identified susceptibility loci such as that located on NRIP1 or ESR1 at a lower cost. 
A well-known locus on CASP8 has also been identified though a candidate gene 
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approach and confirmed in a large sample size study by BCAC (120). Moreover, since 
breast cancer susceptibility loci have moderate effect sizes, a candidate gene approach is 
feasible for the use of current molecular knowledge to perform pathway based analyses. 
Besides, interaction effects are important in the study of the etiology of breast cancer, 
and this could also be investigated in a candidate gene study.  
  
14.5 Rare variants 
Based on the common-disease, common-variant (CDCV) hypothesis, common diseases 
are assumed to be influenced by many genetic and environmental factors, each with 
moderate effect on the trait. Therefore, most public SNP databases and the HapMap 
project catalogue common variants (MAF>5%), which have more statistical power to 
detect such effects. In this thesis, we have focused entirely on common variants. 
However, rare alleles are known to account for approximately 27% of the familial risk of 
breast cancer (42). In addition to genes like BRCA1 and BRCA2 and TP53, which harbor 
extremely rare variants of high penetrance, other familial genes such as checkpoint 
kinase 2 (CHEK2), partner and localizer of BRCA2 (PALB2), BRCA1-interacting 
protein 1(BRIP1), and human homolog of Saccharomyces cerevisiae (RAD50) also 
harbor variants that are rare (MAF< 5%) and associated with intermediate risk of 
developing breast cancer. Such risk variants would not be detected in an indirect genetic 
association study using a tag SNP approach, no matter how large the sample size or how 
many common variants are genotyped because of the weak correlations between higher 
frequency tag SNPs and rare variants (228).  Instead, direct association testing through 
sequencing candidate genes, exomes, or whole genomes need to be applied, where 
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variants are discovered and analyzed. Complementary with GWAS and candidate gene-
based association studies, genome sequencing and rare variant analyses are likely to 
provide valuable new insights into the genetic architecture and underlying biology of 
breast and endometrial cancer susceptibility(32). With the rapid development of next 
generation sequencing technologies such as Illumina HiSeq, ABI SOLiD, and Roche 
454 as well as sequence-based target enrichment methods, analyses of rare variants in 
large numbers of samples are becoming cost effective and are likely to provide further 
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 15 Conclusion and Future Study 
 
Breast cancer is the most common cancer in women, and endometrial cancer is also 
among the most common cancers in women. The first objective of this study was to 
identify susceptibility genetic variants among estrogen related genes for breast and 
endometrial cancer. The second objective was to ascertain that pathway-based multiple 
SNP analysis has greater power for detecting and more chance for revealing consistent 
association evidence than single SNP analysis, especially when the genetic risk is carried 
by multiple risk alleles each with moderate effect. The third objective was to find the 
possible modifiable factors that influence the effects of the identified susceptibility 
genetic variants on breast / endometrial cancer risk. 
 
Our study demonstrated that: 
1. The estrogen metabolism pathway plays an important role in both breast cancer and 
endometrial cancer development. It has been shown that polymorphisms within the 
androgen-to-estrogen conversion sub-pathway is associated with both breast and 
endometrial cancer in the Swedish population. The significant association was validated 
in the Finnish sample of breast cancer. Gene-based AML analysis suggested CYP19A1 
and UGT2B4 to be the major players within the sub-pathway. 
2. For a complex disease like breast cancer, tumor subtype analysis should be taken into 
account, as the confined phenotype could help to reduce the heterogeneity of the 
complex phenotype of being studied and increase the chance of external validation. The 
significant association between the androgen-to-estrogen conversion sub-pathway and 
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postmenopausal women with sporadic estrogen receptor positive tumors was identified 
in the Swedish population and validated in Finnish study. 
3. Effect modification has been identified between ER and ER cofactor gene 
(PPARGC1B) in ER-positive breast cancer. Based on the genetic study finding, we 
further demonstrated the induction of PPARGC1B expression by estrogen stimulation 
and the enhanced occupancies of ER and RNA polymerase II within the region of SNP 
association, indicating the up-regulation of PPARGC1B expression by ESR1 activation 
in biological experiments. However, our finding should be interpreted with great caution 
and primarily be considered as hypothesis generating, as these studies have not directly 
demonstrated the causality between these observations.  
4. Though a comprehensive analysis of common genetic variants within the ER cofactor 
genes by using individual SNP and genes / complex-based test, we have not found any 
consistent evidence of association with the risk of endometrial cancer in the European 
population. Further studies will be needed to examine if common variants with weaker 
effect or rare variants within these genes may play a role in influencing endometrial 
cancer risk.  
 
As a source of extrogenous estrogen, the use of HRT is a risk factor for breast cand 
endometrial cancer in women, although it provides effective relief of climacteric 
women’s syndrome. Based on the finding in the estrogen metabolism study, additional 
studies are needed to explore the interaction effect between using HRT use and the 
genetic variants on the sub-pathway of estrogen metabolism. Further stratification of 
high-risk women under HRT  use could benefit perimenopausal women (232). 
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To date, the most successful methods for prevention or treatment of breast cancer have 
involved interference of estrogen activity either by blocking the ER (with agents such as 
tamoxifen and raloxifene) or by reducing estrogen concentrations by inhibiting the 
enzyme aromatase (with drugs such as anastrozole, letrozole and exemestane). Some 
evidence showed that estrogen metabolism genes and ER cofactors play an important 
role in the selective estrogen receptor modulator (SERM) and tamoxifen resistance in 
breast cancer treatment (125). Meanwhile, although most breast and endometrial cancers 
are hormone-driven carcinomas, follow-up of tamoxifen treatment for breast cancer 
demonstrated that women who undergo treatment are at a somewhat increased risk of 
developing endometrial cancer due to stimulated proliferation by endocrine therapy. 
This evidence (53) revealed that the contradictory action of tamoxifen in the breast and 
endometrium depends on a combinatorial collaboration between the estrogen receptor 
and a specific cellular cofactor protein, which target specific genes in endometrial cells.  
For further investigation of the genetic association between ER cofactor genes and 
breast and endometrial cancers risk, targeting resequencing methods are warranted to 
examine the effects of rare variants. Given the limited sample size, the confined 
phenotype may help to identify genetic variants in a heterogeneous disease. 
 
One of the ultimate goals of public health research is personalized medicine. However, 
rare variants of high penetrance are unlikely to be identified by GWAS and candidate 
gene approaches, which have been focused on studying common variants. It is hoped 
that next-generation sequencing (NGS) data will shorten the road to personalized 
medicine (233). Breast and endometrial cancers are heterogeneous disease. Clearly 
subclassification of heterogeneous diseases is a fundamental goal of personalized 
medicine. Mircoarray studies have improved our understanding from the morphology 
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and clinicopathological level to the molecular subtypes. Moving forward, whole exome 
sequencing or single-cell sequencing may even allow the evaluation of intra-tumor 
heterogeneity(234). Furture treatment and therapies could be tailored to target the unique 
spectrum of mutations that define individual tumors and tumor subpopulations. In one 
example, a novel mutation in the gene, X-ray repair cross complementing gene-2 
(XRCC2(235)), identified though whole exome sequencing of breast cancer, not only 
provides a new target for chemotherapy, but also paves the way towards the era of 
personalized medicine.  
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Appendex 1 Literature about genetic variants within ER cofactor genes in relation to breast cancer and endometrial cancer. 
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Appendix 2 . Genes and number of SNPs used in analyses in the estrogen metabolism pathway. 

















AKR1C4 10 5225926 5252412 33 11 83% 
COMT  22 18307834 18338950 58 10 74% 
CYP11A1 15 72415693 72448634 31 6 90% 
CYP11B1 8 143949280 143959738 6 2 40% 
CYP11B2 8 143987483 143997761 9 4 78% 
CYP17A1 10 104578782 104588780 8 5 75% 
CYP19A1 15 49286046 49419599 53 14 93% 
CYP1A1-2 15 72797437 72837494 12 5 37% 
CYP1B1 2 38146750 38158296 9 5 83% 
CYP21A2 6 32114061 32117398 4 0 - 
CYP3A4-5 7 99082259 99221244 18 6 98% 
GSTP1 11 67106142 67112207 22 1 - 
HSD11B1 1 207924633 207976418 57 9 95% 
HSD11B2 16 66021037 66030453 13 6 50% 
HSD17B1 17 37953258 37962250 23 6 82% 
HSD17B2 16 80624864 80691138 38 11 91% 
HSD17B3 9 98035910 98105755 64 8 88% 
HSD17B4 5 118814603 118907426 38 8 63% 
HSD17B7 1 161027120 161049231 11 5 82% 
HSD17B8 6 33280397 33282585 13 4 33% 
HSD3B1 1 119849849 119860704 52 7 91% 
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NAT1 8 18111895 18125099 16 7 80% 
NAT2 8 18293035 18303003 14 7 100% 
NQO1 16 68299308 68319534 19 7 60% 
SOD2 6 160018641 160035843 10 5 83% 
SRD5A1 5 6685000 6724173 13 5 69% 
SRD5A2 2 31601660 31660973 30 7 88% 
SULT1E1 4 70740020 70761959 12 7 88% 
STS  X 7145997 7284180 45 9 92% 
SULT1A1-2 16 28509267 28543875 12 6 47% 
SULT2A1 19 53064182 53082905 24 8 95% 
SULT2B1 19 53745741 53795995 39 12 97% 
UGT1A1-9 2 234189593 234348188 84 12 99% 
UGT2B11 4 70100636 70115038 93 7 83% 
UGT2B4 4 70378974 70397712 24 7 89% 
   Total 1007 239  
*:Based on the Mar 2006 human reference sequence (NCBI Build 36). 
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ARA70 6 5 10 11 90% 0.993 
Calmodulin1 7 4 7 14 50% 0.995 
Calmodulin2 8 6 20 24 83% 0.968 
Calmodulin3 6 4 4 6 66% 1 
E6-AP 7 7 48 48 100% 0.977 
SRC-2  24 27 154 154 100% 0.985 
L7 5 5 7 7 100% 0.985 
NCoA-62 11 8 42 48 87% 0.985 
RAP46 3 2 7 10 70% 0.985 
SPT6 4 4 7 7 100% 0.985 
BAF57_SWI/
SNF 3 3 18 18 100% 0.985 
TIF1α 9 8 47 48 97% 0.985 
Tip60 54 47 229 248 92% 0.985 
TRAP/DRIP 8 6 29 31 93% 0.985 
ASC-1 7 7 25 25 100% 0.985 
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ASC-2 5 5 49 49 100% 0.985 
CARM1 6 4 13 16 81% 0.985 
PRMT1 4 3 4 5 80% 0.985 
CoCoA 10 8 26 28 92% 0.985 
RPF-1 31 34 128 128 100% 0.985 
PGC-1 51 40 131 162 80% 0.985 
CAPER-alpha  5 4 36 39 92% 0.985 
CAPER-beta  8 7 20 21 95% 0.985 
CoAA 3 2 2 3 66% 0.985 
Cyclin D1 5 4 5 6 83% 0.985 
CEBPB 5 4 3 3 100% 0.985 
CREBBP 21 18 23 23 100% 0.985 
NCOA1 23 19 106 106 100% 0.985 
NCOA7 38 33 115 115 100% 0.985 
PPARG 35 30 112 112 100% 0.985 
DDX5 7 5 16 16 100% 0.985 
EP300 10 10 42 42 100% 0.985 
NCOA3 20 18 98 98 100% 0.985 
PELP1 9 6 18 18 100% 0.985 
PPARGC1A 55 46 97 100 97% 0.985 
SRA1 6 5 11 11 100% 0.985 
NCoR1 4 3 57 74 77% 0.985 
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SMRT 14 10 12 19 63% 0.985 
SHARP  3 3 6 6 100% 0.985 
SAFB1  5 4 14 18 77% 0.966 
SAFB2  10 9 15 16 93% 0.985 
Nrip1 
(RIP140) 9 8 17 20 85% 0.967 
LCoR  5 5 38 38 100% 0.962 
COUP-TF  3 3 4 4 100% 1 
DP97  3 2 7 8 87% 1 
NSD1 10 8 38 43 88% 0.977 
MTA1 4 4 5 5 100% 0.991 
REA 3 2 1 1 100% 1 
FKHR  11 9 32 34 94% 0.962 
TR2  13 11 23 27 85% 0.985 
NEDD8 5 4 6 8 75% 1 
TAF-1β 18 15 136 148 91% 0.959 
Smad4 3 3 24 24 100% 0.993 
mSiah2 4 2 4 6 66% 0.957 
Erβ 20 20 70 70 100% 0.966 
BRCA1 7 5 42 46 91% 0.991 
NCOR2 93 67 131 144 90% 0.972 
NROB2 7 5 6 6 100% 1 
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RBM9 21 16 21 21 100% 0.982 
NR0B1 12 9 9 9 100% 0.993 
Total  806 675         
Criteria: MAF>=0.05 
*  Number of captured SNPs divide total SNPs number 
†  Average r^2 of those captured SNPs 
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Appendix 4. List of statistically significant breast cancer susceptibility loci in genome-wide association studies till April 2012 (Adapted from the 
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  though the BCAC; 7 
additional breast 
cancer GWAS data 
obtained from 
imputation to the 
HapMap 2 Utah 
residents of Northern 
and Western 
European ancestry 
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16q12.1 
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